Roman Vangoitsenhoven is Assistant Professor at the Catholic University of Leuven (KU Leuven), Belgium, and a clinical endocrinologist at UZ Leuven, with a special interest in obesity and type 2 diabetes. He studied the role of diet in the development and treatment of type 2 diabetes for his PhD thesis (2016), and subsequently studied obesity and bariatric surgery at the Cleveland Clinic (2019). His research work has been awarded by the Belgian Endocrine Society, the Belgian (BASO) and the European Association for the Study of Obesity (EASO, New Investigator Award in Basic Science in 2021).

Duality of interest: None declared 

Date: Autumn 2023

Andrew Advani is a Staff Endocrinologist, Clinician Scientist/Associate Professor and the Keenan Chair in Medicine at St Michael’s Hospital and University of Toronto, Canada. He graduated in Medicine with Honours from Edinburgh University, UK, in 1996 and became a Member of the Royal College of Physicians of Edinburgh in 1999. He obtained his PhD from Newcastle University, UK, in 2003. Between 2003 and 2008, Andrew completed his postgraduate endocrinology training in the North East of England and also undertook post-doctoral fellowships in Melbourne, Australia (2005) and Toronto (2006-2007). His research interests are focused on understanding the mechanisms that cause diabetes’ long-term complications, especially diabetic kidney disease. He has received several awards, including the Dr Charles Hollenberg Young Investigator Award from the Canadian Society of Endocrinology and Metabolism in 2015, a Diabetes Investigator Award from Diabetes Canada in 2017, and an Outstanding Health Professional Award from Diabetes Canada in 2020. He is engaged in medical education at the undergraduate and postgraduate levels, graduate student training and a number of knowledge-translation activities engaging persons living with diabetes.

Duality of Interest: None declared

Date: Autumn 2022

Ehtasham Ahmad is an ST7 trainee in Diabetes and Endocrinology based at Kent, Surrey and Sussex Deanery. He is also undertaking a PhD in diabetes at the University of Leicester, UK. Before coming to UK, he graduated from Khyber Medical College in Peshawar, Pakistan.

Dr Ahmad’s research and academic interests include novel pharmaceutical therapies in type 2 diabetes management, including GLP-1 receptor agonists and SGLT-2 inhibitors. Dr Ahmad has been a runner-up for the National Institute for Health Research (NIHR) Clinical Research Network (CRN) Awards in the Rising Star category, for his research work during the COVID-19 pandemic. He has published in high impact journals including LANCET.

Duality of Interest: None declared
Date: Winter 2022

Muhammad Fahad Arshad is a Diabetes and Endocrinology Specialist and Clinical research fellow at the University of Sheffield. His research interests include hypoglcycaemia in diabetes, parathyroid and adrenal disorders.

Dr Arshad has been awarded a national Leadership and Development award from the Society for Endocrinology. He serves as an examiner for the Professional and Linguistic Assessments Board (PLAB) exam conducted by the General Medical Council, as well as a member of the Specialty Certificate Exam (SCE) in Endocrinology question-writing group.

Duality of Interest: None declared
Date: Autumn 2023

Parizad Avari is a Speciality Trainee Specialist Registrar in diabetes and endocrinology and an Honorary Clinical Lecturer at Imperial College London, UK. Her main academic interests lie within the field of type 1 diabetes and novel technologies, including minimally invasive glucose sensors and closed-loop insulin delivery systems. She completed her PhD evaluating a smartphone based real-time personalised decision-support system for people with Type 1 diabetes in 2020.

She is actively involved in medical education, at an undergraduate and postgraduate level, and is involved in supervision of BSc and MRes students at Imperial College London.

Duality of Interest: None declared

Date: Autumn 2022

Salem Beshyah (MBBCh, FRCP) is adjunct Professor of Clinical Research and Metabolic Medicine at the Dubai Medical College for Girls, UAE. He qualified from the Medical School of Tripoli in 1981 and began his clinical training there before moving to the UK in 1985 to train in Leicester and Bedford, where he developed an interest in the practical management of diabetes, cultural issues in diabetes care and clinical management of diabetic foot disease. Subsequently, he undertook a four-year clinical research fellowship in London centred on the clinical and metabolic consequences of hypopituitarism and growth hormone deficiency, which was the subject of his PhD thesis. He was appointed as consultant physician in diabetes and endocrinology in Harlow, Essex, UK, a position he held for 10 years providing diabetes and endocrine services for East Hertfordshire and West of Essex.

His clinical and research interests include the practical management of diabetes, endocrine disorders during pregnancy, the diabetic foot and cardiovascular disorders in diabetes. He has published many peer-reviewed articles and book chapters. He is also associate editor of the Ibnosina Journal of Medicine and Biomedical journal. He is the honorary treasurer of the Libyan association for diabetes and endocrinology and is a Board Member for the Gulf Chapter of the American Association of Clinical Endocrinologists.

He has been a Royal College of Physicians tutor and has co-ordinated a busy CME programme in diabetes and endocrinology.

Duality of Interest: None declared
Date: Summer 2023

Kåre Birkeland (MD, PhD) is a certified specialist in Internal Medicine and Endocrinology, working as a full-time Professor of Internal Medicine at University of Oslo and Senior Physician at Oslo University Hospital, Rikshospitalet, Norway. He is chair of Oslo Diabetes Research Centre.

He has previously held positions as Head of the Department of Endocrinology, Morbid Obesity and Preventive Medicine in Oslo University Hospital and Director of Research at Aker University Hospital, Oslo, Norway. His research interest and main publications are in clinical intervention studies, epidemiological studies and mechanistic studies of subjects with prediabetes, gestational diabetes or type 2 diabetes.

Professor Birkeland has been a national coordinator and member of steering committees and data-safety and monitoring committees in a number of large clinical, multi-centre studies. He has published more than 250 papers in international, peer-reviewed journals and was formerly a member of the Council of the European Association for the Study of Diabetes (EASD). He was Associate Editor of the European Journal of Endocrinology 2015-2022, and is currently member of the editorial board of the Journal of the Norwegian Medical Association and of the board of the Scandinavian Society for the Study of Diabetes. He is Chairman of the Medical Scientific Board of the Norwegian Diabetes Association. He is head of the Council that oversees the last year of the Medical curriculum at Faculty of Medicine, University of Oslo, he has supervised more than 15 PhD students, a number of Master and Bachelor students and has been the mentor of a number of postdocs and senior researchers.

Duality of Interest: None declared
Date: Autumn 2022

Andrew Boulton (MB, BS, MD, FRCP) graduated with honours in medicine from the University of Newcastle-upon-Tyne in 1976. He subsequently obtained the MRCP (UK) in 1979 and was elected FRCP in 1992. He obtained his MD in the complications of diabetes from the University of Newcastle-upon-Tyne in 1985. After clinical training in Newcastle upon Tyne, Sheffield and later Miami, he was subsequently appointed Professor of Medicine in 1995 with a special interest in diabetes and its complications at the University of Manchester, and Consultant Physician at Manchester Royal Infirmary. His clinical role includes inpatient supervision of patients with diabetic complications and outpatient clinics at the Manchester Diabetes Centre.

His research into diabetic neuropathy and diabetic lower limb problems started more than 40 years ago and he has had grant support over the last few decades from Diabetes UK, EFSD, American Diabetes Association, NIH/NIDDK and others.  He was previously editor of Diabetic Medicine and was senior associate editor for Diabetes Care for 20 years until 2022.  He has published more than 600 peer-reviewed papers.

He is a former Chair of Postgraduate Education, Vice-President and President of the EASD. Until recently (December 2022), he was President of the International Diabetes Federation. His services to international diabetes have been recognised by the award in 2008 of the American Diabetes Association Harold Rifkin Award for distinguished international service in the field of diabetes.

Although part-retired, he still teaches undergraduate and postgraduate students in diabetes and its complications and is a trainer recognised by the GMC.

Duality of Interest: Professor Boulton has received Speaker’s/Honorarium and Board member/ advisory panel fees from AOT Inc.
Date: Spring 2023

Frank Bowling (BSc[Hons], PgD[Plast], MSc, DPM, PhD, DSc) is Professor in Surgery and Translational Medicine and a Consultant Podiatric Surgeon at the University of Manchester, Manchester Royal Infirmary. His specialist area of interest is the care of patients with lower limb complications due to a loss of protective sensation/tissue damage. He holds higher postgraduate diplomas in Microsurgery (Pius Branzeu Centre) endorsed by the European Board of Plastic Reconstructive Microsurgery and Neurology under the auspices of the Academy of Sciences ASM. He also holds adjunct posts: Clinical and Academic (Instructor) Professor of Surgery Victor Babes, RO and Nicolae Testemițanu, RM Universities, Schools of Medicine and Pharmacy. 

Professor Bowling oversees various research clinics based at Manchester Foundation Trust and Manchester, Bolton High-Risk Diabetic foot clinics, under his long-term mentor Professor Andrew Boulton. As a senior clinical academic he is responsible for planning clinical trials/research into lower limb complications with a specialist interest in diabetes and developing collaborative research projects with colleagues, both nationally and internationally. He has published more than 130 peer-reviewed journal articles, including numerous books and chapters.

He is a fellow of the Faculty of Podiatric Surgery, College of Podiatry, Directorate of Podiatric Surgery, London, UK and a fellow of the Faculty of Podiatric Medicine, Royal College of Physicians and Surgeons of Glasgow, UK; over sees Academy Sciences Romania and Moldova and is a fellow of the Royal College of Physicians (Edin). He leads undergraduate and postgraduate teaching in diabetes and its complications manifested in the lower limb.

Duality of Interest: None declared
Date: Spring 2023

Kristina Casteels is a paediatric endocrinologist at Belgium’s largest university hospital, UZ Leuven. Kristina obtained her medical degree at the Catholic University of Leuven in 1993. In 1998, she successfully defended her PhD thesis titled ‘1,25-dihydroxyvitamin D3 and its analogues as immunomodulators in autoimmune type 1 diabetes: mechanisms of action and preclinical applications’ (under the supervision of Professor Chantal Mathieu). After an internship in Münster and a scholarship in Oxford, she started as paediatric endocrinologist in the University Hospital Leuven and is also assistant professor at the University of Leuven.

As an academic clinician, she expanded the Child and Adolescent Diabetes Department at UZ Leuven into a national and international reference centre with a strong diabetes team in which the care of children and adolescents is central. The number of patients has gradually increased over the past few years and the treatment has also intensified significantly. In 2013 the centre became a SWEET centre of reference after a very positive evaluation by an external peer review process. Since 2015, Kristina Casteels has also been a member of the SWEET Data, Publication and Presentation Committee (DPPC) and co-author of several publications together with this study group.

Professor Casteel’s research focuses on the prevention of diabetes. She is the principal investigator for GPPAD (the Global Platform for the Prevention of Autoimmune Diabetes) in Belgium and co-ordinates programmes that identify infants with an elevated genetic risk of developing type 1 diabetes and prevention studies in these babies. She is also part of INNODIA, a Clinical Network for better understanding of type 1 diabetes with the aim of preventing it.

Kristina is actively involved in medical education at the undergraduate and postgraduate levels within the university hospital. This includes the education of medical students covering paediatrics and interns covering endocrinology and diabetes. Outside of the university hospital Kristina leads training sessions for paediatricians and endocrinologists and contributes to the continuing education of general practitioners, parents and teachers.

Duality of interest: Professor Casteels has received research support / grants form Medtronic and speaker’s honorarium fees also from Medtronic.

Date: Summer 2023

Ana María Cebrián graduated in medicine and surgery from the University of Valencia in 1995 and then went on to complete a PhD from the same university. She currently works as a family doctor in the Murcian Health Service, Cargena, Spain, and as an associate professor at the San Antonio Catholic University of Murcia.

She is also a university professor at Miguel Hernández University of Elche, a lecturer, diabetes researcher and a member of numerous international professional medical societies, such as the Spanish Society of Family Medicine, where she is a member of the Diabetes Research Group of the Spanish Diabetes Association, among others. She is the author of more than 100 national and international publications and regularly speaks at scientific meetings. She has received multiple grants, awards and prizes. She is also a member of the executive committee of Primary Care Diabetes Europe (PCDE).

Duality of Interest: None declared
Date: Summer 2023

Pratik Choudhary is Professor and Honorary Consultant in Diabetes with a special interest in type 1 diabetes and technology at the University of Leicester, and Honorary Consultant at the University Hospitals of Leicester NHS Trust.

After finishing his medical training in India, he completed an MD thesis on the use of continuous glucose monitoring in the study of hypoglycaemia from Sheffield, before moving to King’s College London. There, he was clinical lead for type 1 diabetes as well as the islet and pancreas transplant programme.

Professor Choudhary has active clinical and research programs around education, psychology and technology in type 1 diabetes. In particular, his research uses neuroimaging to explore the mechanisms of hypoglycaemia unawareness, and the use of different strategies, such as technology and behavioral interventions, to restore awareness. He is work-package lead for the Hypo-RESOLVE consortium, within which he is principal investigator of Hypo-METRICS, a large multinational study evaluating the biological and psychosocial impacts of sensor-detected hypoglycaemia. He has been involved in a number of national and international research studies, as well as a number of national and international training and education programs for diabetes. He has published over 150 papers in peer-reviewed journals as well as over 10 book chapters.

He is currently chair of the Diabetes Technology Network-UK, working to improve access to technology for diabetes through training, education and advocacy.  He is also a member of the EASD postgraduate education committee and the medical advisory panel on diabetes to the department of transport in the UK as well as an associate editor for Diabetic Medicine.

Duality of Interest: : Professor Choudhary has received research support / grants from Abbott, Medtronic and Novo Nordisk, and speaker’s honorarium / fees from Abbott, AstraZeneca, Dexcom, Glooko, Insulet, Lilly, Medtronic, Novo Nordisk, and Sanofi. He has also received payments for membership of boards/advisory panels from Abbott, Dexcom, Lilly, Medtronic and Sanofi.

Date: Winter 2022

Xavier Cos (MD, PhD, Msc) is an Associate Professor of Medicine at the Autonomous University of Barcelona, Spain. He is also a general practitioner (GP) and Innovation Officer at the Institut Catala de la Salut, Barcelona. He graduated in 1997, defended his PhD in 2021 and currently works as a GP in Sant Martí Primary Health Centres (Catalonian National Health Service) and as Head of Innovation in Primary Care Barcelona-city in Primary Care Barcelona, Spain. 

Professor Cos’ main areas of interest are research and education in primary care, with a special emphasis on the diabetes field. He is a member of the Primary Care University Research Institute Jordi Gol and currently is its European representative in diabetes and endocrine disorders. At this research institution he is an active member of two working groups: diabetes prevention, and epidemiological database analysis. He was also the Spanish national representative of the European General Practice Research Network, WONCA Europe research Group (www.egprn.org) on behalf of the Spanish Primary Care society (www.semfyc.es) from 2009 to 2015. 

He started his active involvement in diabetes at GEDAPS Primary Care Diabetes Study Group (www.redgdps.org) in 1997, working on diabetes treatment. In Spain, he has been working in many institutional projects for the Catalonian Health Department (type 2 diabetes treatment guidelines, SBMG recommendations, and the Diabetes Expert Patient Programme). He is regularly invited to participate in national and international meetings, to lecture as an expert on diabetes in primary care or to develop and conduct educational activities. He also participates in many advisory boards and expert groups. He is currently working on various research projects in diabetes prevention (DP Transfers), CATRisc, DE-PLAN, DISCOVER, LadyDiab, VERIFY and OBINDIAB. His unit has recently been involved in numerous randomised clinical trials (dapagliflozin, lixisenatide, early treatment with MET+Vilda). He is also involved in the academic field as an Associate Professor at the medicine department of the Universitat Autonoma de Barcelona since 2009 and is currently an associate editor of the Primary Care Diabetes journal. In 2009, he was elected as vice chairman of Primary Care Diabetes Europe (PCDE -www.pcdeurope.org) and since February 2016 as Chairman elect. In 2021, he was appointed as Chairman of PCDE for a term of four years.

Dan Cuthbertson (BSc, PhD, FRCP) is Professor and Honorary Consultant Physician in the Department of Cardiovascular and Metabolic Medicine at the University of Liverpool.

His research interests include obesity and related complications.

Professor Cuthbertson is author of 150 scientific papers, which have published across a wide range of medical and scientific journals, including the BMJ, Lancet, Nature Reviews Endocrinology, Frontiers in Endocrinology, Diabetologia, Frontiers in Nutrition. Journal of Clinical Endocrinology and Metabolism, European Journal of Endocrinology, Diabetic Medicine, Diabetes Care and Diabetes Therapy. He is actively involved in the education and training of graduates and postgraduates.

Duality of Interest: Professor Cuthbertson has received research support / grants from Astra Zeneca, Ipsen and Novo Nordisk and speaker’s fees/honoraria from Astra Zeneca, Ipsen, Eli Lilly and Novo Nordisk. He has also received payments for consultancy fees from Astra Zeneca, Ipsen and Eli Lilly. 

Date: Summer 2023

Ilenia D’Ippolito, MD, a specialist in endocrinology and metabolic diseases, qualified as a medical doctor at the University of Rome Tor Vergata. She subsequently started her training in diabetes and the field of diabetic neuropathy under Professors Vincenza Spallone and Davide Lauro. She was Visiting Fellow at Pierre et Marie Curie University (Paris IV) in the departments of Endocrinology and Internal Medicine. She is now a PhD student in Systems and Experimental Medicine at the University of Rome Tor Vergata.

Ilenia is a member of the Italian Society of Diabetes, the Italian Society of Endocrinology, the Italian Association of Endocrinology, Neurodiab (Diabetes Neuropathy Study Group) and the European Association for the Study of Diabetes (EASD) where she has presented her works in oral presentation sessions.

Her interests include diabetic neuropathy, painful diabetic neuropathy, autonomic neuropathy, type 1 diabetes and technologies and gestational diabetes. Her activities also include group-education sessions for diabetic patients promoting training strategies about healthy lifestyle with an individualised approach to the management of diabetes and its complications.

Duality of Interest: None declared

Date: Winter 2022

Thomas Danne is Director of the Department of General Paediatrics, Endocrinology/Diabetology and Clinical Research at the Auf der Bult Hospital for Children and Adolescents, Hannover Medical School, Germany. He is a former Research Fellow of the Joslin Diabetes Centre, Harvard Medical School, USA.

His research interests include basic and clinical research in paediatric diabetology, particularly new insulins, insulin pumps, glucose sensors and the artificial pancreas. He has published more than 300 research papers and is a principal investigator of international multi-centre studies. These include the DREAM consortium for treating children with diabetes with automated-insulin delivery.  Currently, he is Chairman of the SWEET project which aims to reduce inequalities in access to and quality of pediatric diabetes care worldwide with more than 150 contributing diabetes centers worldwide. He is also a work-package leader of the INNODIA project, a global partnership providing a pan-European reference point for conducting studies to prevent or cure type 1 diabetes.

Professor Danne has various society affiliations, including as Past President of the International Society for Paediatric and Adolescent Diabetes (ISPAD), the International Diabetes Federation, and Past President of the German Diabetes Association.

Duality of Interest: Professor Danne has received research support/grants from Abbott, Astra Zeneca, Boehringer, Dexcom, Eli Lilly, Medtronic, NovoNordisk and Sanofi, and speaker’s fees/honoraria from Abbott, Astra Zeneca, Dexcom, Eli Lilly, Medtronic, NovoNordisk, Roche and Sanofi. He has also received payments for membership of boards/advisory panels from Abbott, Astra Zeneca, Dexcom, Eli Lilly, Medtronic, NovoNordisk, Roche and Sanofi and has Stocks/Shares/ Directorships with DreaMed.

Date: Summer 2022

Umesh Dashora (MD, FRCP, MA, FRCP, MD) is a consultant in endocrinology and diabetes at the East Sussex Healthcare NHS Trust. He is also an honorary clinical Professor and deputy sub dean at Brighton and Sussex Medical School and an honorary clinical senior lecturer at King’s College London. He is a member and regional adviser of the Royal College of Physicians, London, and Royal College of Physicians, Edinburgh, and a member and meeting secretary of the Association of British Clinical Diabetologists.

His clinical and research interests include insulin treatment in type 2 diabetes, high-strength insulins, pregnancy and diabetes, and sodium glucose co-transporter inhibitors. He regularly sees both outpatients and inpatients with all types of diabetes and endocrine-related problems.

Prof Dashora is an executive member of the Joint British Diabetes Societies for Inpatient Care (JBDS-IP) and has contributed to a number of guidelines for inpatient care. He has led the annual JBDS-IP Rowan Hillson Inpatient Safety Award since its launch in 2014 to promote excellent practice in insulin and inpatient safety.

He is also a member of the executive committee for the Association of British Clinical Diabetologists (ABCD) and has led on a number of position statements from the ABCD to help standardise patient care for people with diabetes. He also contributes to the British Journal of Diabetes & Vascular Disease as a news editor.

Prof Dashora has a long-standing interest in medical education, having completed an MA in Medical Education at Brighton Medical School and he also graduated from the NHS Leadership Academy Mary Seacole programme. Working with colleagues and the Royal College of Midwives, he has been actively involved in the development of an online structured education and training programme for midwives managing diabetes in pregnancy.

He is also engaged in medical education at the undergraduate and postgraduate levels by way of organising and overseeing seminar programmes, simulations, clinical placements, objective structured clinical examinations, interviews, supervision of research projects and prescribing courses for nurses. He also works as a personal tutor to a group of medical students throughout their course.

Duality of Interest: None declared
Date: Spring 2023

Melanie Davies is Professor of Diabetes Medicine at the University of Leicester and an Honorary Consultant Diabetologist at the University Hospitals of Leicester NHS Trust, Leicester, UK. She is based in the Diabetes Research Centre, University of Leicester and is also the Co-Director of the Leicester Diabetes Centre, which has over 160 research staff, at the University Hospitals of Leicester NHS Trust. She trained at Sheffield and then completed her training at Cambridge, Ipswich and Leicester.

Professor Davies’ research interests include the causes, screening, prevention, self-management and treatment of type 2 diabetes mellitus. She is a National Institute for Health Research Senior Investigator Emeritus and Director of the NIHR Leicester Biomedical Research Centre. Professor Davies is the Principal Investigator on a number of large global studies in the field of diabetes, obesity, physical activity, sedentary behaviour and cardiovascular disease and has served as an expert for the UK’s National Institute for Health and Care Excellence (NICE) on a number of guideline groups. She was co-chair of EASD/ADA’s recent Consensus Report on Type 2 Diabetes Mellitus Management.

Professor Davies has published over 800 original articles in national and international peer-reviewed journals, such as the Lancet, NEJM and BMJ and has over £90M of peer review grant funding. She has authored more than 510 published abstracts and 10 book chapters and is Co-editor of the diabetes section in the 2011 Oxford Textbook of Endocrinology and Diabetes. She was awarded the CBE (Commander of the Most Excellent Order of the British Empire) in the 2016 New Year’s Honour’s List for services to diabetes research and awarded Fellowship of the Academy of Medical Sciences in 2018. 

Duality of Interest: Professor Melanie Davies has received research support /grants in support of investigator and investigator initiated trials from Boehringer Ingelheim, Novo Nordisk, Lilly, Sanofi, AstraZeneca Janssen and Eli Lilly and speaker’s honorarium / fees from Boehringer Ingelheim, Novo Nordisk, Lilly, Sanofi, Astra Zeneca, Napp Pharmaceuticals, Novartis and Amgen. She has also received board member / advisor panel fees from Boehringer Ingelheim, Novo Nordisk, Lilly, Sanofi, AstraZeneca, Pfizer, ShouTi Pharma, Lexicon and Medtronic together with consultancy fees from Boehringer Ingelheim, Novo Nordisk, Lilly and Sanofi.

Date: Autumn 2023

Asma Deeb is the chief of Paediatric Endocrinology and the chair of research and ethics committee at Shaikh Shakhbout Medical City, Abu Dhabi. She is a clinical professor at the Gulf University, UAE.

Professor Deeb trained in the UK where she obtained an MD degree in growth hormone gene expression in 2002 from the University of Newcastle. She was appointed as a Clinical Lecturer in Paediatric Endocrinology at the University of Cambridge between 2001 and 2005. She has a special interest in disorders of sexual differentiation, use of technology in the management of children with diabetes and the genetics of diabetes mellitus.

Professor Deeb has authored and co-authored more than 100 peer-reviewed publications. In 2019 she was first author of the ISPAD Clinical Practice Consensus Guidelines: Fasting during Ramadan by young people with diabetes, published in Paediatric Diabetes.

Professor Deeb is currently President of the Arab Society of Paediatric Endocrinology and Diabetes (ASPED) and the ASPED representative of the Global Pediatric Endocrinology Association. She is the Chair of Communication of the European Society of Paediatric Endocrinology (ESPE) and a member of the advisory board of the International Society of the Pediatric and Adolescent Diabetes (ISPAD). Professor Deeb has recently hosted the second ASPED conference, and four ASPED/ISPAD postgraduate courses and she has organised four ASPED/ESPE schools.

Duality of Interest: None declared
Date: Spring 2023

Ketan Dhatariya graduated from the University of London in 1991 and did his diabetes and endocrinology training in and around London. For 2 years during his training he was also a part time General Practitioner in the evenings. He took some time out of his training to spend a year doing intensive care medicine and anaesthetics. After he finished his diabetes training in 2001 he went to do a 2 year research fellowship in endocrinology at Mayo Clinic in Minnesota, USA. He was appointed as a consultant in diabetes, endocrinology and general medicine at the Norfolk & Norwich University Hospital in 2004, and Honorary Professor of Medicine at the University of East Anglia in 2019. 

He is a full time NHS clinician, with no dedicated research time or funding. His predominant areas of interest are inpatient diabetes – in particular peri-operative diabetes care, the management of diabetes related emergencies, and the ‘diabetic foot’. He leads one of the largest foot clinics in the East of England.

Professor Dhatariya has several national roles in the UK. He is currently the Chair of the Association of British Clinical Diabetologists and is also the immediate past chair of the Joint British Diabetes Societies Inpatient Care Group where he led or co-authored several national guidelines on the management of various aspects of inpatient diabetes care. He is the Chair of the Examining Board for the UK Specialist Clinical Exam in Diabetes and Endocrinology. He is also the immediate past President of the Diabetes and Endocrine section of the Royal Society of Medicine. He is the Section Co-editor for diabetes for www.endotext.org. He is an Associate Editor of Diabetic Medicine and, until 2023 was also an Associate Editor of BMJ Open Diabetes Research & Care.

Professor Dhatariya has over 185 peer reviewed publications, and has published over 20 book chapters on inpatient diabetes, peri-operative diabetes care or on the diabetic foot. He has been named as one of the world’s leading diabetes experts by www.expertscape.com

Duality of Interest: Professor Dhatariya has received speaker’s fees/honoraria from AstraZeneca, Menarini, Novo Nordisk and Abbot. He has also received payments for other educational activities from AstraZeneca, Menarini and Novo Nordisk.

Date: Summer 2023

Parkash Dhindsa is a specialist diabetes dietitian working at the University Hospitals of Derby and Burton NHS Foundation Trust with a special interest in the management of obesity in patients with diabetes. She gained a BSc (Hons) degree from King’s College London and has worked in the NHS for more than 40 years.

In 1995, she was awarded a PhD from the University of Nottingham for a programme of research that included investigating the acceptability, feasibility and benefits of meal replacements to provide low-energy diets in obese patients with type 2 diabetes and symptomatic hyperglycaemia. The results, presented at the Diabetes UK conference in 2001 and published in Diabetic Medicine in 2003, showed significant metabolic benefits, with reductions in both body mass index and total cholesterol levels with residual benefits still being apparent after one year.

Dr Dhindsa has a long-standing interest in education, both for health professionals and patients and their families. She has held a number of educational roles at the University of Nottingham, including as a clinical tutor in the Graduate Entry Medical School where she trained as a problem-based learning facilitator and was part of the team that established a four-year Graduate Entry Medical Programme. She has also worked as a teacher practitioner in the School of Nutrition and Dietetics, led small group teaching sessions and contributed to assessment writing programmes.

She is the lead Dose Adjustment For Normal Eating (DAFNE) educator for Derby and Burton Hospitals University Trust and has recently been part of a team developing a programme of masterclasses in the management of diabetes for primary care staff across Derbyshire.

Duality of Interest: None declared
Date: Summer 2023

Nancy Samir Elbarbary is Professor of Paediatrics in the Faculty of Medicine at Ain Shams University, Egypt. She gained her doctorate degree (MD) from Ain Shams University in 2007 and passed her MBBCH and Masters (MSc) in paediatrics (Excellent with honours) in 1998 and 2003, respectively. She works in the Paediatric Diabetes Clinic, which is one of the first paediatric clinics at the Children’s Hospital and in the Middle East – and one of the largest referral centres in Egypt for managing children with type 1 diabetes.

She is a member of several professional societies, including the International Society for Pediatric and Adolescent Diabetes (ISPAD), the European Society of Pediatric Endocrinology (ESPE), the Egyptian Society of Childhood Diabetes and Endocrinology (ESPED) and the Arab Society for Paediatric Endocrinology and Diabetes (ASPED). She has contributed to the ESPE e-learning programme and participated in ISPAD Guidelines 2018, and in the IDF-DAR Diabetes and Ramadan Practical Guidelines 2021 ‘Management of type 1 diabetes when fasting during Ramadan’. She also participated in the International Consortium of Polycystic Ovarian Syndrome in Adolescence and is now working on a chapter update of ISPAD Guidelines 2022. She translated the JDRF-supported website ‘Beyond type 1 diabetes’ into the Egyptian Arabic language.

Professor Elbarbary has been a member of the ASPED-ISPAD Diabetes Academy steering committee since 2016 and the head of the diabetes committee and scientific research in ASPED. She has been an invited speaker at regional meetings of professional specialty societies, international meetings and symposia.

She serves as an invited reviewer for more than 30 international peer-reviewed journals and is a member of the editorial board of more than 10 international journals, as well as a member of the research and ethics committee at Ain Shams University hospital, Cairo. She has published over 50 papers in international and local periodicals and journals, and supervised more than 60 theses. She has also supervised and helped in the writing of ‘Protocol of management of DKA in type 1 diabetes,’ developed specifically for Egyptian doctors treating children with diabetes.

Professor Elbarbary has participated as a principal investigator in trials sponsored by diabetes associations and is involved in many other international clinical and basic research projects as country representative of the Egypt in TEENs registry study, FITTER and SWEET. She has received several international professional prizes, awards, grants and special recognitions from various Egyptian academic societies and from the Academy of Scientific Research and Technology for distinguished international publications. She has also been awarded in the name of the country’s president, Abdel Fattah El-Sisi, the First-Class Medal of Honour Award for Medical Science and State Academic Recognition Achievement.

Duality of Interest: None declared
Date: Winter 2022

Lena Eliasson is Professor in Experimental Diabetes Research at Lund University, Sweden and her research group works in association with Lund University Diabetes Centre (LUDC) and EXODIAB. She received an MSc in engineering physics from Chalmers University of Technology, Gothenburg, Sweden, in 1992 and was awarded a PhD in cellular physiology from the University of Gothenburg in 1997, before completing postdoctoral studies at Lund University. 

Her expertise is within the field of type 2 diabetes and cystic fibrosis-related diabetes and the control of insulin and glucagon secretion. Her research focus is to understand how to circumvent the reduced capacity of the pancreatic beta cells to secrete enough insulin, and why the control of alpha cell glucagon secretion becomes disturbed in diabetes. She has used the patch-clamp technique to investigate ion-channels and exocytosis in pancreatic alpha- and beta-cells. More recently, she combines this with the examination of miRNA networks important in the regulation of insulin secretion. Her research aims to understand cellular mechanisms underlying impaired islet hormone secretion contributing to the pathogenesis of diabetes.

She is research group leader for the Islet Cell Exocytosis unit in the Department of Clinical Sciences in LUDC Malmö. In her role at LUDC, formed through a Swedish Research Council Linnaeus grant over 10 years ago, she collaborates with colleagues to perform functional follow-ups of both epigenetic and genetic observations from humans. These studies aim to increase the understanding of insulin- and glucagon secretion in the complex disease diabetes.

Duality of Interest: None declared
Date: Spring 2023

Marc Evans (MB, BCh) is a consultant diabetologist at University Hospital Llandough in Cardiff, where he has been in post since 2003. Previously, he was a consultant diabetologist at University Hospital Llandough and the University Hospital of Wales, and a lecturer in diabetes and endocrinology at the University of Wales College of Medicine.

Dr Evans has a very active research interest, particularly in the fields of health economics, health outcomes, epidemiology and pharmacoepidemiology. He has published over 200 peer reviewed papers and abstracts across these fields and has also supported various Health Technology Assessment submissions for differing novel therapies across a variety of disease areas. He is currently editor in chief of Diabetes Therapy, a journal specifically focused on therapeutic issues in diabetes.

Duality of Interest: Dr Evans has received research support/grants from Novo Nordisk, speaker’s honorarium/fees from Novo Nordisk, Boehringer and AstraZeneca, payments for board membership/advisory panels from Novo Nordisk and Boehringer and consultancy work from AstraZeneca and HEOR Ltd.

Date: Autumn 2022

Malin Fex is Associate Professor at Lund University Diabetes Centre, Sweden. She received both her master’s degree in cell and molecular biology and PhD in medical science from Lund University.

Her research goals are to understand why the pancreatic beta cells fail to produce adequate amounts of insulin to regulate whole body metabolism in type 2 diabetes. One of her key focuses is monoamine signalling within the islets of Langerhans and another is mechanisms of autophagy and metabolism in pancreatic beta cells during metabolic stress and type 2 diabetes. She is a researcher at EXODIAB.

Professor Fex is course leader in lectures on metabolic diseases at Lund University and teaches courses on human physiology and endocrine regulation to medical students. She often gives public seminars on diabetes and her research into pancreatic beta cells.

Duality of Interest: None declared
Date: Spring 2023

Patrik Finne is Professor of Nephrology at the University of Helsinki and chief physician at Helsinki University Hospital. His research focuses on risk factors and outcomes for patients on renal replacement therapy and he has published 140 original publications. Over 20 years ago, he initiated the research activities of the Finnish Registry for Kidney Diseases. He continues to lead this research programme and became chairman of the board of the registry in 2021. He has received several awards, including being selected as one of the top 100 healthcare influencers in Finland in 2017.

Professor Finne is actively engaged in postgraduate research education and he is currently supervising four doctoral students (two as principal supervisor at the Doctoral programme in clinical research, University of Helsinki, and two at the University of Eastern Finland). He also serves as a member in several doctoral dissertation committees at the University of Helsinki. Since 2020, he has been responsible for the nephrological training of medical students and specialists in nephrology at the University of Helsinki.

Duality of Interest: None declared
Date: Summer 2023

Miles Fisher graduated from the University of Glasgow in 1979 and was a consultant physician at Glasgow Royal Infirmary from 2001 to 2020. In 2010 he was appointed as an Honorary Professor at the University of Glasgow. He was a Vice-President (Medical) of the Royal College of Physicians and Surgeons of Glasgow from 2011-14, President of the Scottish Society of Physicians for 2015-16 and Co-chair of Scottish Heart Arterial disease Risk Prevention (SHARP) in 2017.

His clinical and research interests include diabetes and the heart, hypoglycaemia and new treatments for diabetes. He was a member of the DIGAMI 2 study steering committee and was the Scottish co-ordinator. He was an events adjudicator for the HOPE, HOPE-TOO and cardiovascular outcome trials, and for the albiglutide Harmony Phase 3 development programme. He has been involved in guideline development for the Scottish Intercollegiate Guidelines Network (SIGN) and the European Society of Cardiology (ESC), and in guideline reviewing for SIGN, ESC, the EASD and NICE.

Professor Fisher is the editor or co-editor of four books on heart disease in diabetes, three books on hypoglycaemia, a book on SGLT-2 inhibitors and a book on antidiabetic drugs. He has authored or co-authored 55 book chapters, 84 original papers, 86 review articles, 37 leaders and editorials, 55 drug notes for Practical Diabetes and 15 drug notes for the British Journal of Cardiology. He was the co-author of the diabetes chapter in the 19th, 20th and 21st Editions of Davidson’s Principles and Practice of Medicine.

Duality of Interest: None declared
Date: Spring 2023

Hannah Forde studied medicine at the National University of Ireland, Galway, and graduated in 2010. She undertook her internship and basic specialist training in general internal medicine at University Hospital Galway and was awarded Membership of the Royal College of Physicians of Ireland (MRCPI) in 2013. She then undertook clinical and laboratory research between Beaumont Hospital and the School of Biotechnology in Dublin City University, respectively, investigating the pleiotropic role of the biomarker ‘TRAIL’ in cardiovascular disease. She was awarded her PhD in 2018. She completed specialist training in endocrinology and diabetes mellitus, and general internal medicine with the Royal College of Physicians of Ireland (RCPI) and was awarded her Certificate of Satisfactory Completion of Specialist Training (CSCST) in 2020. She then completed a subspecialty fellowship in type 1 diabetes at Leicester General Hospital and is currently working as a consultant endocrinologist/diabetologist in Beaumont Hospital in Dublin, Ireland.

Dr Forde has been involved in conducting multiple multi-centre randomised clinical trials. She has authored and co-authored more than 20 peer-reviewed publications and presented at numerous national and international meetings. She is engaged in medical education teaching at both an undergraduate and postgraduate level, and co-led on the development of an MSc module on technology in diabetes with the University of Leicester.

Duality of Interest: None declared
Date: Autumn 2022

Brian Frier is an international authority in diabetes and hypoglycaemia. Formerly a consultant physician in general internal medicine and diabetes at the Royal Infirmary of Edinburgh (1987-2012) and the Western Infirmary and Gartnavel General Hospital, Glasgow (1982-1987), Professor Frier graduated from the University of Edinburgh and completed training in Edinburgh, Dundee and New York, USA, where he was a Research Fellow in Diabetes and Metabolism at Cornell University Medical Centre, New York. He retired from clinical practice in 2012 and is an Honorary Professor of Diabetes at the University of Edinburgh, affiliated to the Centre for Cardiovascular Science at The Queen’s Medical Research Institute.

Professor Frier’s research interests include the pathophysiology of insulin-induced hypoglycaemia in diabetes, including cognitive function, neuroimaging, symptom responses, physiological manifestations and clinical syndromes such as impaired awareness of hypoglycaemia, insulin therapy and driving. He has published extensively in these research interests with over 500 publications and has co-edited two international major textbooks on hypoglycaemia and diabetes. He has also contributed to several international textbooks on diabetes and to ongoing editions of Davidson’s Principles and Practice of Medicine. As an educator, he has mentored 20 postgraduate research fellows working on hypoglycaemia.

Professor Frier was formerly Chair of the Diabetes Research Group in Scotland (2003-2006), Chair of the Honorary Advisory Panel on Driving and Diabetes to the Secretary of State for the Department for Transport (2001-2012), a Member of the Medical Research Council (MRC) Centre for Cognitive Ageing and Cognitive Epidemiology in Edinburgh (2008-2018), and Vice-President of the Royal College of Physicians of Edinburgh (2008-2012). Professor Frier has been a valued speaker at many national and international meetings: in 1986 he gave the RD Lawrence lecture and in 2009 he gave the Banting Memorial lecture at the Diabetes UK Professional Conference, and in 2017, the Camillo Golgi lecture at the 53rd European Association for the Study of Diabetes (EASD) conference. In 2004 he received the Somogyi Award from the Hungarian Diabetes Association for his research on hypoglycaemia. Professor Frier continues to collaborate with colleagues in the UK and abroad on hypoglycaemia research, including the effects on cognitive function and studies on symptomatology, morbidity and epidemiology.

Duality of Interest: Professor Frier has received speaker’s honoraria fees and payment for membership of a board/advisory panel from Eli Lilly and Company.

Date: Autumn 2022

Peter Gaede (MD, DMSc) is Professor of Endocrinology at the University of Southern Denmark, Odense and Chief Physician at the Department of Cardiology and Endocrinology, Slagelse Naestved Ringsted Hospital, Denmark.

He graduated from the University of Copenhagen in 1990 and became a specialist in internal medicine and endocrinology in 2006 and 2010, respectively. He wrote his medical thesis on the importance of intensified multiple risk-factor intervention in patients with type 2 diabetes under the supervision of Professor Oluf Pedersen at the Steno Diabetes Center in Copenhagen, Denmark. For that he was appointed Doctor of Medical Science (DMSc) in 2006.

He was the daily leader of the Steno-2 study, which demonstrated that intensified risk-factor intervention in type 2 diabetes could cut the risk of any diabetes-related complication by 50% and prolong the median life span by almost eight years. Results from the trial have had tremendous impact on recent guidelines for treatment of type 2 diabetes worldwide.

Peter’s principal research activities are focused on type 2 diabetes, cardiovascular disease, kidney disease and therapeutics, as well as economic aspects of treatment and specific interventions. He has played a major role in setting up the magnetic resonance imaging (MRI) of the heart centre at Slagelse Naestved Ringsted Hospital.

Currently, he is the main supervisor for four PhD students and co-supervisor for three others. So far, three students have achieved their PhD degrees under his supervision.

He is a former board member of the Danish Society of Endocrinology and served as a board member the Postgraduate Education Committee under the European Association for the Study of Diabetes (EASD). He has given more than 100 lectures and workshops on diabetes treatment in more than 50 countries.

He has published over 80 articles in peer-reviewed journals, with over 11,000 citations.

Duality of Interest: None declared.
Date: Summer 2023

Júlia Galhardo is a paediatric diabetologist and endocrinologist at the Paediatric Endocrinology and Diabetes Unit, Hospital de Dona Estefânia – Central Lisbon University Hospital Centre and Lisbon Medical Sciences Faculty, Nova Medical School, Lisbon, Portugal. She obtained her PhD in diabetes, obesity and metabolism from the University of Bristol, UK.

One of Professor Galhardo’s long-term research interests is childhood obesity. As long ago as 2011, based on research she undertook in the Department of Clinical Sciences, Institute of Child Life and Health, University of Bristol, she reported that “the timing of food intake affects our weight. Eating fast meals promotes excessive weight gain.” Her clinical and research interests also include the cardiometabolic effect of sugar-sweetened beverages, reduction of obesity in children, use of continuous glucose monitoring and glucose variability in very young children with type 1 diabetes. She has a special interest in insulin resistance in children and adolescents with type 1 diabetes.

She is a reviewer for a range of journals, including Diabetology and Metabolic Syndrome, and is a member of the editorial board of Endocrinology, Diabetes and Metabolism. She has also contributed to a training manual to support healthcare and education professionals working with young people with type 1 diabetes in Portugal. She teaches on the Master’s in clinical nutrition offered by the Lisbon School of Health Technology.

In 2011, she was awarded the Henning Andersen Prize by the European Society of Paediatric Endocrinology.

Duality of interest: none declared

Date: Summer 2023

Daniel Gordin works as a consultant nephrologist at the Helsinki University Central Hospital and Helsinki Hypertension Center of Excellence in Finland. He is a senior lecturer in internal medicine at the University of Helsinki and appointed as an Academy of Finland clinician scientist between 2019 and 2024. Dr Gordin undertook his postdoctoral training as the Mary K Iacocca Senior Research Fellow at the Joslin Diabetes Center, Harvard Medical School, Boston, USA, between 2017-2018. His research focus is on cardiorenal complications.

Duality of Interest: None declared
Date: Summer 2023

Per-Henrik Groop (MD, DMSc, FRCPE) is Professor of Internal Medicine (Chair) at the University of Helsinki, Finland, and Chief Physician at the Abdominal Center Nephrology, University of Helsinki and Helsinki University Hospital. He graduated from the University of Helsinki in 1982, where he later defended his thesis on the relationship between GIP and beta-cell function (1989). Following post-doctoral studies under Professor Giancarlo Viberti at Guy’s Hospital, University of London, he returned to Helsinki as Consultant of Nephrology, later becoming Professor of Nephrology (Chair [2010-2015). He also acted as Adjunct Professor at the Department of Diabetes, Monash University, Melbourne, Australia.

His research is focused on the pathogenesis of diabetic complications, with a special emphasis on diabetic nephropathy. He is Principal Investigator of the Finnish Diabetic Nephropathy (FinnDiane) Study. In 1997, Professor Groop initiated the landmark nationwide FinnDiane Study at the Folkhälsan Research Center in Helsinki. The study, of which Professor Groop is the Principal Investigator, aims to support identification of genes and genetic variants associated with diabetic complications. His FinnDiane Research Group represents an interdisciplinary team of 45 scientists, post-graduate students and personnel.

Professor Groop has served as Associate Editor of Diabetologia (2005–2007) and as a member of the publication’s Advisory Board (2008–2011). He has also served as Associate Editor of Kidney International and International Diabetes Monitor (2007–2011). He was Chairman of the EASD Scientist Training Course (2007–2013), President of the European Diabetic Nephropathy Study Group (EDNSG) between 2008-2010, Chairman of the Signe and Ane Gyllenberg Foundation since 2011, and Honorary Secretary of the EASD 2013-2016. He was awarded the prestigious EASD Castelli Pedroli Prize – 24th Camillo Golgi Lecture in 2009 as well as the Novo Nordisk Foundation Lecture in 2012.

Professor Groop has published more than 350 peer-reviewed original articles in high-impact journals, 33 reviews and book chapters, 47 papers in his native languages Swedish and Finnish, as well as more than 600 abstracts presented at major international meetings.

Duality of Interest: Professor Groop has received speaker’s honorarium / fees from AstraZeneca, Bayer, Boehringer Ingelheim, Medscape, Merck Sharpe Dohme, Mundipharma and Sciarc plus payments for membership of boards / advisory panels from AstraZeneca, Bayer, Boehringer Ingelheim, Medscape, Merck Sharpe Dohme and Mundipharma.

Date: Winter 2022

Wasim Hanif is a Professor of Diabetes and Endocrinology, Consultant Physician, and Head of Service in diabetes at the University Hospital Birmingham. He is a Honorary Professor of Medicine at the University of Warwick. He is the Board Member of the Centre for Diabetes Endocrine and Metabolism, University of Birmingham. He is a visiting Professor at Birmingham City University and the Medical Director of the Advanced Diabetes Course. He is on the Board of Governors as a Trustee of Diabetes UK and a Non-executive Director on the Board of the British Medical Journal.

He is an eminent authority on Diabetes, Obesity, and Ethnic health working with several national bodies, and professional groups in the UK. He has been involved with major research projects in diabetes and has published widely and was selected for Kings Fund Leadership Program. His research interests include diabetic kidney disease, diabetes prevention, cardiovascular disease in diabetes, diabetes in Ramadan, obesity, ethnicity and tackling health inequalities. He is involved as a chief and principal investigator in several international multi-centre trials and was instrumental in setting up UKADS (United Kingdom Asian Diabetes Study).

Professor Hanif has been involved at a parliamentary level advising the government on issues relating to Diabetes and ethnic health. He is the Chair of the Diabetes Working Group and Trustee of the world-recognised South Asian Health Foundation (SAHF). He is a member of the European policy forum on diabetes advising the European Union (EU). His involvement in the National Institute for Health and Care Excellence (NICE) in the UK has been extensive, sitting on the advisory NICE Health Technology Appraisal Committee between 2009 and 2015. He is on the Expert Advisory Committee of Commission of Human Medicine, advising the Medicines and Healthcare products Regulatory Agency (MHRA) on new Medicinal agents.

He is involved in several international projects including the International Diabetes Federation (IDF) World Health Organisation (WHO) Global Policy Forum on Diabetes, Strategy for Commonwealth to guide ministers at a United Nations (UN) summit, Chair of the International advisory board for the ORNATE project India of MRC, member of UK Foreign and commonwealth office Scientific trade delegation among others. He is recipient of several national and international awards including the prestigious South Asian Health Foundation UK Lifetime Achievement Award.

Duality of Interest: None declared
Date: Spring 2023

Simon Heller (DM, FRCP) is Professor of Clinical Diabetes at the University of Sheffield, UK, and Director of Research and Development and Honorary Consultant Physician at Sheffield Teaching Hospitals Foundation Trust, UK. He trained at Queen’s Medical Centre, Nottingham and undertook his research training at the University of Nottingham and Washington University, USA.

Professor Heller is currently a member of the Diabetes UK Research Strategy Group Management Group and a sub-panel chair of the UK NIHR Programme Grants for Applied Research funding scheme. He is also the National Specialty Lead in Diabetes to the UK NIHR Clinical Research Network and an NIHR Senior Investigator Emeritus.

His current research interests include the pathophysiological responses to hypoglycaemia and hypoglycaemia unawareness, the potential contribution and mechanisms of hypoglycaemia to cardiovascular mortality, the use of insulin analogues and other technologies to reduce hypoglycaemia. He chaired the glucose control group of the ADVANCE trial and was the PI on the REPOSE trial measuring the effectiveness of insulin pumps. He also conducts research programmes concerned with developing interventions (including the DAFNE intervention) to encourage more effective diabetes self-management. He chairs the International Hypoglycaemia Study Group, 15 professionals and academics with expertise in diabetic hypoglycaemia who have recently been working with both ADA and EASD to extend the classification of hypoglycaemia. He has authored over 300 original research articles and reviews. From 2000-2005 he was Editor of Diabetic Medicine.

Duality of Interest: Professor Heller has received research support/grants from Medtronic and payments for board membership/advisory panels from Zealand Pharma.

Date: Autumn 2022

Norbert Hermanns has been head of the Research Institute at the Diabetes Centre Mergentheim since 1996. He is also an Adjunct Professor at the University of Bamberg, Germany. His education includes a Masters degree in psychology and he is a certified ‘Psychological Psychotherapist’ and ‘Psychodiabetologist’ of the German Diabetes Association (DDG).

His research interests include behavioural modification and the development and evaluation of self-management programmes for people with diabetes, the acute emotional effects of hypoglycaemia, treatment of hypoglycaemia unawareness, and depression and diabetes.

His professional memberships include: past-Chair of the EASD’s Psychological Aspects of Diabetes Study Group (PSAD), membership of several scientific associations, including BRIDGE, the ADA, the EASD and the DDG. He is a member of the DDG’s Diabetes and Psychology board, as well as the Diabetes Depression Dialogue.

Professor Hermanns’ work has been published in several scientific journals, including The Lancet, Diabetologia, Lancet Diabetology and Endocrinology, Diabetes Care and Diabetic Medicine. He has authored 396 articles, 10 books and 8 book chapters. His current H-index is 47. He has been a member of the editorial board of Diabetes Care from 2017 – 2020.

Duality of interest: none declared

Date: Summer 2023

Richard Holt is Professor of Diabetes and Endocrinology at the University of Southampton and an Honorary Consultant Physician in Diabetes and Endocrinology at the University Hospital Southampton NHS Foundation Trust. He trained at the University of Cambridge and London Hospital Medical College and received a PhD while working as a Medical Research Council Clinical Training Fellow at King’s College School of Medicine and Dentistry, London.

Professor Holt’s current research interests are broadly focused on clinical diabetes but specifically encompass studies of the relationship between mental illness and diabetes and diabetes and pregnancy. Professor Holt leads the diabetes clinics for pregnancy, young adults and people with cystic fibrosis. The pregnancy clinic has undertaken innovative research, which has informed both local and NICE national guidelines. He has significant involvement in postgraduate and undergraduate teaching in Southampton and is also a fellow of the Higher Education Academy.

He is a past chair of Diabetes UK’s Council of Healthcare Professionals, contributing to several Diabetes UK guidelines and position statements. He was a member of the 2008 NICE diabetes and pregnancy guideline development group and the NICE Type 2 diabetes: preventing the progression from pre-diabetes programme development group. He is an expert in doping with growth hormone and acts as an adviser to UK Sport and international anti-doping agencies.

Professor Holt is the past Editor-in-Chief of Diabetic Medicine, and has published over 250 articles in peer-reviewed journals and has previously authored textbooks, including the Textbook of Diabetes. Professor Holt is the vice-chair of the EASD Committee for Clinical Affairs and was the EASD co-chair of the EASD-ADA consensus report of the management of type 1 diabetes in adults.

His contributions have been recognised with awards from numerous foundations, including Diabetes UK, the European Society for Paediatric Gastroenterology Hepatology and Nutrition (ESPGHAN) and HM Queen’s honours list.

Duality of Interest: Professor Holt has received research support/grants from Novo Nordisk and speaker’s fees/honoraria from Novo Nordisk and Eli Lilly & Company.

Date: Winter 2022

Mahmoud Ibrahim is a Consultant Endocrinologist and Director EDC, Center for Diabetes Education, USA. He is a graduate of the Ain Shams University Faculty of Medicine in Cairo, where he continued his postgraduate studies in Internal Medicine and Endocrinology in 1988, gaining a masters in endocrinology.

Dr Ibrahim has been a member of the advisory board of the department of endocrinology and diabetes at the University Campus Bio-Medico, Rome, Italy since 2014. He is also a consultative board member for EMRO (East Mediterranean Office WHO), a faculty member of the Danish Diabetes Academy, Copenhagen, Denmark and a member of the Michigan Center for Diabetes Translational Research MCDTR, Ann Arbor, Michigan USA.

His clinical research interests and publications include the prevention and management of diabetes and its complications including during Hajj and Ramadan; diabetes education and its impact on clinical outcomes and hypoglycaemia and its management. He has received important honours and awards including the Paul Ghaliongi memorial lecture in October 2000, the American Diabetes Association’s 2009 Harold Rifkin Award for Distinguished International Service in the Cause of Diabetes, the East Mediterranean University Cyprus Annual Conference Award 2014 and the International Diabetes Federation Award in 2017.

His scientific activities include serving as editor of a number of scientific journals such as Clinical Diabetes (Middle East Edition) an official journal of the American Diabetes Association (ADA) 2002–13, Diabetes Care (Middle East Edition) 2002-15, and he is currently the editor of the International Journal of Diabetes and Endocrinology North Africa Region. He has been an abstract reviewer of important scientific conference and congresses around the world. He is currently a reviewer of peer-reviewed journals including the British Medical Journal, Diabetes Care and the Lancet Diabetes and Endocrinology.

Duality of Interest: None declared
Date: Summer 2023

Hinde Iraqi is Professor of Endocrinology and Metabolic Diseases in the Faculty of Medicine and Pharmacy at Mohammed V University in Rabat. She is also the pedagogical manager for the university Diploma in Diabetology at the University of Montpellier and Editor-in-Chief of the Journal of Endocrinology and Diabetology in Morocco.

Professor Iraqi is a member of multiple scientific societies of diabetology and endocrinology, and her areas of interest are the therapeutic alliance, growth hormones and thyroid disease. She has published more than 100 papers, including Diabetes and Ramadan: Practical Guidelines 2021 and The glycaemic personality: A SURE framework of person-centred choice in diabetes care. She is an expert trainer in the Diabetes Conversation Map and member of the Diabetes & Ramadan International Alliance (DAR) working group.

An important current project of hers is developing a strategy with the Ministry of Health in Morocco for a simple and global approach to diabetes from a population and individual perspective.

Duality of Interest: None declared
Date: Summer 2023

Stefan Jansson is a scientist at the University Health Care Research Centre, Department of Medical Sciences, Örebro University, Sweden. Since 1996, he has worked as a general practitioner at the Brickebacken Health Care Centre in Örebro, Sweden, and is a specialist in general medicine.

His PhD was judged as the best PhD thesis of the year in 2014. Dr Jansson has contributed to national and international meetings and is a board member of Primary Care Diabetes Europe (PCDE). His areas of interest include quality improvement in diabetes care with a focus on improving treatment for patients with type 2 diabetes and preventing or postponing the risk of complications.

He is currently working on a range of research projects in diabetes and has published papers in national and international journals. He is also a reviewer of manuscripts for numerous scientific journals. He is actively engaged in clinical education, including medical students at Örebro University, and is a supervisor for medical students in essay writing and doctoral students.

Duality of Interest: None declared
Date: Summer 2023

Peter Jones is Professor of Endocrine Biology in the Department of Diabetes at the Guy’s campus of King’s College London. He is also currently head of the Physiology Teaching Department. He obtained his PhD at the National Institute for Medical Research in London, studying peptide hormones in the central nervous system.

Professor Jones started working on beta cell function in diabetes as a postdoctoral fellow at Queen Elizabeth College in 1984. He was awarded an RD Lawrence Fellowship by Diabetes UK, followed by a Medical Research Council Senior Research Fellowship, after which he took up an academic position as a lecturer in Physiology at King’s College London.

He was awarded the Diabetes UK RD Lawrence Lecture for 1997 and the Dorothy Hodgkin Lecture for 2015 in recognition of his work on beta cell function. His research interests remain with the beta cell, with current focus on islet transplantation therapy for type 1 diabetes and on novel therapeutic targets for type 2 diabetes.

He has published over 250 peer-reviewed articles, with his most recent papers including ‘Sulfated progesterone metabolites that enhance insulin secretion via Trpm3 are reduced in serum from women with gestational diabetes mellitus’ in Diabetes and a commentary in Diabetic Medicine.

Duality of Interest: None declared

Date: Autumn 2022

Sabine Kahl completed her medical training at Saarland University, Homburg/Saar, Germany in 2008. In parallel, she performed her doctoral training at the Institute of Clinical and Experimental Pharmacology of Saarland University, exploring the L-type calcium channel β2 proteins and their influence on calcium current in murine heart, graduating with distinction in 2009. She continued her career at the Medical Faculty and University Hospital of Düsseldorf as well as at the Institute for Clinical Diabetology at the German Diabetes Center, Düsseldorf and joined the research group ‘Energy Metabolism’ led by Professor Michael Roden in 2016. She is currently the deputy head of the group.

In 2020, Dr Kahl completed her board certification in clinical pharmacology. Her research interests include the pathogenesis, diagnosis and treatment of type 2 diabetes and its concomitant diseases, with particular focus on non-alcoholic fatty liver disease (NAFLD). She has authored more than 20 publications in international journals and has received a number of awards for her work. Dr Kahl teaches medical students at the Heinrich-Heine-University Düsseldorf in the area of diabetes and comorbidities and also supervises medical doctoral theses.

Duality of Interest: Dr Kahl has received research support/grants from the German Center for Diabetes Research (DZD e.V.) and the German Diabetes Association (DDG)

Date: Autumn 2022

Janaka Karalliedde (FRCP, FHEA, PhD) is a Clinical Reader at the School of Cardiovascular Medicine and Sciences at King’s College London, UK, and Consultant Physician in Diabetes and Endocrinology at Guy’s and St Thomas Hospital London. He graduated with a distinction in medicine from the University of London and was awarded a UK Medical Research Council Clinical Research Training Fellowship in 2004.  He has published widely in the subject of diabetic kidney disease and cardiovascular disease. Dr Karalliedde runs specialist clinics for people with diabetic kidney disease and has led the development of cardiorenal community diabetes clinics focussed on early identification and intervention in people with diabetes at high risk of cardiovascular and kidney disease. He teaches undergraduate and postgraduate students at King’s College London and is actively involved in clinical education of healthcare professionals nationally and internationally.

Duality of Interest: Dr Karalliedde has received speaker’s honorarium / fees from Boehringer Ingelheim and Astra Zeneca and board member / advisor panel fees from Boehringer Ingelheim
Date: Summer 2023

Yanislava Karusheva undertook her medical training at Charite Berlin, Germany, and the Medical University, Sofia, Bulgaria. She is a clinician scientist at the Institute for Clinical Diabetology of the German Diabetes Center in Düsseldorf, Germany. She is currently working as a visiting clinical academic fellow at the Wellcome-MRC Institute of Metabolic Science and the Addenbrooke’s Hospital in Cambridge under the guidance of Professor Sir Stephen O’Rahilly. Her interests include clinical nutrition and metabolism, insulin resistance, obesity treatment and deep metabolic phenotyping. In 2018, Dr Karusheva completed the EASD Robert Turner Course in Oxford. In 2021, she received the Hans Adolf Krebs Award of the German Nutrition Society, the DDG Sponsorship Award of the German Diabetes Association and the Walter Benjamin Scholarship of the German Research Foundation for her fellowship in Cambridge. Her most recent research focuses on the different roles of GDF15 and rare diseases.

Duality of Interest: None declared
Date: Autumn 2023

Eleanor Kennedy has a BSc in Biochemistry from the University of Glasgow in Scotland and a PhD in molecular neuropharmacology from the University of Leicester in England. Following three years as a postdoctoral student at the University of California, San Diego, working on thrombin-mediated gene expression in the brain, Dr Kennedy worked at the University of Geneva in Switzerland studying the intracellular signalling pathways that stimulate insulin secretion.

She subsequently undertook a full-time MBA at Cranfield School of Management, which was followed by four years as Research Manager and Director at Diabetes UK. Since 2005, she has run her own company – ED Kennedy Consulting Ltd – and has worked for a wide range of clients. These include the NIHR Diabetes Research Network, the NIHR Dementia and Neurodegenerative Disease Research Network, the Juvenile Diabetes Research Foundation, Diabetes UK, the Diabetes Research and Wellness Foundation, the Diabetes Wellness Network Sweden, the Academy of Medical Royal Colleges, the Royal College of Pathologists, the Department of Health and the European Foundation for the Study of Diabetes.

With over a decade of teaching experience with the Open University and in running diabetes diploma initiatives with the British Medical Journal and in setting up other blended learning projects for clients in the Middle East, Eleanor also continues to be a regular contributor to diabetes publications covering research and development for lay and specialist audiences.

In 2018, Dr Kennedy was commissioned to create and build the platform for the EASD’s e-learning programme and continues this work today as Programme Director for the project.

Duality of interest: None declared
Date: Autumn 2023

Julie Kerr-Conte (BSc, MSc, PhD) is Professor of Cell Biology/Cell Therapy at the University of Lille, France, where she works in the INSERM U1190 team on Translational Research for Diabetes. She completed a BSc from SUNY Albany, New York in 1986, her MSc from the University of Wisconsin, Madison in 1990 and her PhD from the Science and Technology University, Lille 1 in 1995.

She is responsible for research and clinical grade human islet isolation (French FDA [ANSM]-approved process) and Director of the core Biotherapies Platform since 2012 (French FDA-approved facility) Deputy Director, INSERM U1190 Translational Research for Diabetes. She is a recognised technical expert and a faculty member of NICE Networks of Islet Cell Transplantation in Europe. She is responsible for the manned Biotherapies Platform, authorised by the French FDA for auto- and allograft cell therapy of diabetes (230 islet allo/autotransplants).  She has published more than 200 articles in peer-reviewed journals.

Professor Kerr-Conte is a member of the EASD (since 1995), the International Pancreas and Islet Transplantation Association, International pancreas and Islet transplantation association (IPITA), and chair of the European Islet and Pancreas Transplantation Association affiliated with the European Society for Organ Transplantation.

Duality of interest: none declared

Date: Autumn 2023

Kamlesh Khunti (FRCGP, FRCP, MD, PhD, FMedSci) undertook his medical training at the University of Dundee. He is Professor of Primary Care Diabetes and Vascular Medicine at the University of Leicester and Leicester General Hospital, UK. He is also co-director of the Leicester Diabetes Centre and leads a research group that is currently working on the early identification of, and interventions with, people who have or are at increased risk of developing cardiometabolic diseases. His wider research interests focus on primary care and public health, ethnic health; cardiometabolic diseases, multiple long term conditions and pragamatic interventional studies real-world evidence.

Professor Khunti has published more than 1200 articles, including a large number on COVID-19. His work has influenced national and international guidelines on the screening and management of people with diabetes He is a member of the UK’s Scientific Advisory Group for Emergency (SAGE) and Chair of the Ethnicity Subgroup of SAGE.

Professor Khunti is also Director of the UK National Institute for Health Research (NIHR) in Applied Research Collaborations East Midlands and Director of the Real-world Evidence Unit and Centre for Ethnic Health Research. He is a Senior Investigator and principal investigator on several major national and international studies. He is the National NIHR ARC Theme Lead for Multiple Long Term Condtions and Ethnicity and Diversity. He is also Honorary Visiting Professorial Fellow with Department of General Practice, University of Melbourne.

Professor Khunti is also a Fellow of the Academy of Medical Sciences and is currently an advisor to the Department of Health, a Clinical Advisor for the National Institute for Health and Care Excellence (NICE)He is Member of the KDIGO Diabetes and CKD Guideline Group and a member of the American Diabetes Association Standards of Care Guidelines for Diabetes. He is past chair of the NICE Guidelines on Prevention of Diabetes. He has won numerous awards nationally and internationally and was awarded the Commander of the Order of the British Empire (CBE) in the 2022 New Year’s Honour’s List for services to health.  

Duality of Interest: Professor Khunti has received research grants / supports from AstraZeneca, Boehringer Ingelheim, Lilly, Merck Sharp & Dohme, Novo Nordisk, Roche and Sanofi and speaker’s Honorarium / fees from AstraZeneca, Boehringer Ingelheim, Janssen, Lilly, Merck Sharp & Dohme, Novo Nordisk, Roche and Sanofi. He has also received consultancy payments form Amgen, AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Lilly, Merck Sharp & Dohme, Novo Nordisk, Roche, Sanofi and Servier.
Date: Summer 2023

Mikael Knip (MD, PhD) has been a Professor of Paediatrics at the University of Helsinki since 2000 and Chief Physician at the HUCH Children’s Hospital up to 2018, as well as a project manager at the Department of Paediatrics, Tampere University Hospital. Currently he works as a Research Director at the University of Helsinki. He graduated from the University of Oulu with a licentiate degree in medicine in 1976 and a doctorate in medicine in 1983.

Professor Knip’s research focuses on type 1 diabetes and other immune-mediated diseases in children and adolescents. He has published more than 600 original papers and over 200 other scientific articles. He has been one of the principal investigators on the Finnish Diabetes Prediction and Prevention (DIPP) study from its start in 1994. 

In 2017, he received the Matti Äyräpää Award for research into the origins of childhood diabetes. Recently he received the J.W. Runeberg Award for pioneering work in the field of type 1 diabetes. He has also received an honorary doctorate from the Faculty of Medicine of the University of Tartu, the Johnny Ludvigsson Science Prize in recognition of long-term and successful research into childhood diabetes, and the Maud Kuistila Prize for Merited Educator of Medical Researchers.

Duality of Interest: None declared

Date: Spring 2023

Filip K Knop (MD, PhD) is a Professor of Endocrinology and Director of the Center for Clinical Metabolic Research at Gentofte Hospital, University of Copenhagen, and Consultant Endocrinologist at Steno Diabetes Center Copenhagen.

Professor Knop has been involved in diabetes and metabolic research since his fellowship at The Distinguished Gifford Laboratories for Diabetes Research, University of Texas, Southwestern Medical Center in Dallas in 1999 (supervised by Professor Christopher B Newgard). His research centres on human metabolism, the pathophysiology of obesity and related disorders including type 2 diabetes and non-alcoholic fatty liver disease, regulation of appetite and food intake, and the therapeutic potential of factors involved in these processes. The Knop laboratory has reported several novel findings describing the integrative role of the gut and the liver in human pathophysiology.

Professor Knop has authored more than 460 peer-reviewed scientific publications and he has received several honours for his research, such as being named “Rising star” by the EASD in 2010, the DPLU/LUDC Nordic Prize for an Outstanding Young Diabetes Investigator (2011), Johan Quentin and Wife’s Prize for Outstanding Research (2014), The Capital Region of Denmark’s Global Excellence Prize (2014), The Thomsen Prize (2015), The Niels Schwartz Sørensen Prize (2017), The Danish Odd Fellowship’s Research Prize (2017), the European Journal of Endocrinology Prize 2018, and the Minkowski Prize 2019. Professor Knop has extensive teaching experience within the fields of human physiology and anatomy, internal medicine, clinical endocrinology and diabetology; and he has successfully supervised 50 PhDs.

Duality of Interest: Professor Knop has received research support / grants from Novo Nordisk and Zealand Pharma and speakers honorarium / fees from Astra Zeneca, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Sanofi and Zealand Pharma. He has also received payments for membership of boards / advisory panels from Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Sanofi and Zealand Pharma and fees for other educational activities from Astra Zeneca, Eli Lilly, Novo Nordisk and Zealand Pharma; together with payments for consultancy from Astra Zeneca, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Sanofi and Zealand Pharma.
Date: Summer 2023

Eelco de Koning is Professor of Diabetology at the Leiden University Medical Center (LUMC), The Netherlands. He received his medical doctorate at the University of Utrecht in 1991 and started research into islet biology and pathology at the Diabetes Research Laboratories in Oxford, UK, which resulted in a PhD in 1994. He later obtained a fellowship from the Joslin Diabetes Center at Harvard Medical School in Boston, Massachusetts, where he worked in translational beta-cell therapy and research projects on human islets and stem cell biology. He is credited for his bench-to-bedside approach and initiation of national and international multicentre research programmes on improvement of islet transplantation and use of stem cells for islet replacement therapy for patients with diabetes.

Professor de Koning’s research group focuses on the islets of Langerhans with a long-term goal to generate insulin-producing cells from alternative cell sources for novel cell replacement therapy in diabetes. He is the Head of the LUMC Diabetes Center and Medical Director of the human islet isolation and transplantation unit and co-ordinates the human islet transplantation programme as a national service in The Netherlands. He also plays a key role in the National Expertise Center on Maturity-Onset Diabetes of the Young (MODY) and is principal investigator in the regenerative medicine consortia RegMedXB and ReNew, which develop novel cell-replacement strategies for patients with severe beta cell failure.

Professor de Koning is a past-president of the European Pancreas and Islet Transplantation Association (EPITA). He has received a Career Development Award from the Dutch Diabetes Research Foundation, and the Dr F Gerritzen Award from the Dutch Association for Diabetes Research for his work in the field.

Duality of Interest: None declared

Date: Autumn 2022

Meera Ladwa (MRCP, PhD) is Clinical Lead for Young Adult, Transition and Type 1 Diabetes at Newham University Hospital, London, UK. She graduated from Imperial College London School of Medicine in 2008 and was awarded her doctorate in diabetic medicine by King’s College London in 2021, where she studied beta cell function in black African men. In January 2022, she was appointed as an Honorary Senior Clinical Lecturer at Queen Mary University London.

Her clinical and research interests include diabetes in young adults, diabetes in pregnancy and diabetes in ethnic minorities. She is accredited as a medical educator by the Royal College of Physicians.

Duality of Interest: None declared
Date: Autumn 2023

Carel Le Roux is Professor of Metabolic Medicine at Ulster University, Coleraine, UK and Chair of Chemical Pathology and Metabolic Medicine at University College Dublin, Ireland together with being a Director of the Metabolic group. He also holds the position of Professor of Metabolic Medicine at Ulster University and Extra-ordinary Professor of Chemical Pathology at University of Pretoria. Professor Le Roux graduated from medical school in Pretoria, South Africa and went on to complete his PhD at Imperial College London.

An expert in metabolic medicine, Professor Le Roux’s areas of interest include obesity, chemical pathology, bariatric medicine and lipidology. He specialises in managing patients undergoing bariatric surgery and pharmacotherapy, to reduce complication risks and optimise the health benefits of weight loss. His research activity focuses on the mechanisms of bariatric surgery, the relationship between the gut and the brain and how signals between them can be optimised, and, primarily, increased mortality and morbidity associated with obesity and diabetes.

Professor Le Roux currently holds a number of editorial roles for journals including Surgery for Obesity and related Disease, and Obesity Surgery. He has been published extensively, served on international advisory boards and delivered numerous invited, keynote and plenary lectures in his field of expertise. A lecturer at undergraduate level, national and international conferences, Professor Le Roux has also supervised several MSc, MD and PhD students. He built an independent research group and published many high-impact papers with great influence. In particular, his translational research on the understanding of the physiological role and pathological changes in appetite control and the impact of bariatric surgery on diabetes has been widely acknowledged.

Professor Le Roux has been a member of the Novo Nordisk, GI Dynamics, Keyron, Johnson & Johnson and Herbalife Nutrition Advisory Board, is a member of Experts in Severe and Complex Obesity (ESCO) and the Association for the Study of Obesity and the Irish Society for Clinical Nutrition and Metabolism. He has received the Science Foundation Ireland (SFI) President of Ireland Young Researcher Award, Irish Research Council Laureate Award, a Clinician Scientist Award from the National Institute Health Research (NIHR) and a Wellcome Trust Clinical Research Fellowship, amongst many other prestigious awards and grants. He is currently the coordinator of the Innovative Medicine Initiative SOPHIA project www.imisophia.eu

Duality of Interest: Professor Le Roux has received speaker’s fees/honoraria from Herbalife, Novo Nordisk, Boehringer Ingelheim, Eli Lilly and Johnson & Johnson. He has also received payments for membership of boards/advisory panels from Herbalife, Novo Nordisk, Boehringer Ingelheim, Eli Lilly, Johnson & Johnson, GI Dynamic, Glia Pharmaceuticals and Medtronic.  

Date: Spring 2023

Nader Lessan (MBBS, MD, FRCP) is Consultant Endocrinologist and Clinical Lead for Research at the Imperial College London Diabetes Centre in Abu Dhabi, United Arab Emirates (UAE). He undertook his undergraduate, clinical and postgraduate medical training in the United Kingdom, including Newcastle, London, Manchester and Cambridge. Since then he has spent nearly two decades working in the UAE. He is a Fellow of the Royal College of Physicians.

His research interests are focused on the medical aspects of Ramadan (in particular, glucose monitoring for people with diabetes), vitamin D deficiency, biomarkers and predictors of complications in diabetes, the genetics of obesity, energy metabolism, and the role of adenovirus 36 in obesity and diabetes and the medical sequelae of COVID 19 infection. He has authored numerous research papers and speaks at major conferences around the world. He is also a co-author of the DaR/IDF Ramadan Guidelines.

Dr Lessan is Visiting Reader at Imperial College London and is the founder and programme director for the Imperial Diabetes Educator Training (IDET) course.

Duality of Interest: None declared
Date: Winter 2022

Catarina Limbert is a Consultant in Paediatrics and Paediatric Endocrinology and Diabetes at University Hospital Dona Estefânia in Lisbon, Portugal, and holds a Clinical Chair in Child and Adolescent Health at the NOVA Medical School, Universidade Nova de Lisboa. She qualified at medical school in Lisbon and she trained in paediatric endocrinology and diabetology in Austria at the Paediatric Endocrinology Clinics and Endocrinology Laboratory at the University of Graz.

Her principal research interests are on type 1 diabetes pathophysiology, in particular immune mechanisms, molecular genetics and cell-based therapies, which led to her PhD in Medicine, received from the University of Würzburg and University of Lisbon in 2011. She combines her healthcare practice with research activities of both a basic and clinical nature which has led to several publications in the field of paediatric endocrinology and diabetes. She is a member of the advisory board for Portugal’s national diabetes programme. Since 2017 she has been President of the Portuguese Society for Paediatric Endocrinology and Diabetes. She is actively involved in the International Society for Pediatric and Adolescent Diabetes (ISPAD).

Duality of Interest: None declared

Date: Summer 2023

Charlotte Ling is a Professor in Diabetes Research at Lund University, Sweden, and a principal investigator in the Epigenetics and Diabetes Unit at Lund University Diabetes Centre (LUDC). She obtained her PhD in endocrinology at the University of Gothenburg in 2002.

After a postdoctorate at Lund University, where she studied the genetics of type 2 diabetes, she dedicated her research to the study of epigenetic mechanisms causing type 2 diabetes and metabolic disease. Her research group has pioneered the field of epigenetics in type 2 diabetes and have made several groundbreaking discoveries, such as genome-wide epigenetic modifications in pancreatic islets, skeletal muscle, adipose tissue and the liver from patients with type 2 diabetes compared with control subjects without diabetes.

Her research group has also shown that genetic and non-genetic factors such as single nucleotide polymorphisms (SNPs), exercise, diet, obesity and age alter the genome-wide epigenetic pattern in human primary tissues for type 2 diabetes.

She is frequently invited to write review papers and book chapters, and to give lectures on the topic of epigenetics in type 2 diabetes by, for example, the American Diabetes Association (ADA), International Diabetes Federation (IDF), Keystone Symposia and the Endocrine Society.

Professor Ling is still dissecting the impact of epigenetics in the pathogenesis of type 2 diabetes. More recently, she has been trying to translate her epigenetic findings to biomarkers and novel therapies for precision medicine to improve prediction, prevention and treatments of type 2 diabetes.

She has been awarded research grants from numerous national and international foundations, including a ten-year ‘Distinguished Professor Award’ from the Swedish Research Council, a five-year Novo Nordisk ‘Distinguished Investigator Grant’ in endocrinology and metabolism and grants from the European Commission (Horizon 2020 and European Research Council).

Professor Ling has published numerous papers in leading scientific journals. Notable recent publications include ‘Novel subgroups of type 2 diabetes display different epigenetic patterns that associate with future diabetic complications’ in 2022 in Diabetes Care, ‘VPS39-deficiency observed in type 2 diabetes impairs muscle stem cell differentiation via altered autophagy and epigenetics’ in 2021 in Nature Communications and ‘Epigenetic markers associated with metformin response and intolerance in drug-naïve patients with type 2 diabetes’ in Science Translational Medicine, 2020.

Duality of Interest: None declared

Date: Winter 2022

Mehdi Maanaoui is a nephrologist at the University of Lille, specialising in kidney transplantation. His passion for cell transplantation led him first to the Netherlands in the laboratory of Prof Ton Rabelink (Leiden University Medical Center) and then to the islet laboratory of Prof François Pattou (Inserm U1190 – EGID), Lille, France. He is currently undertaking a PhD programme exploring methods to improve clinical islet transplantation, especially for people with type 1 diabetes undergoing kidney transplantation. He has authored more than 20 publications, mainly in transplantation and teaches nephrology and transplantation in the University of Lille.

Duality of Interest: None declared

Date: Winter 2022

Rayaz Malik graduated in Medicine from the University of Aberdeen in 1991, obtained his MRCP (London) in 1996, PhD from the University of Manchester in 1997 and was elected to become a fellow of the Royal College of Physicians in 2007. He was appointed as Consultant Physician and Senior Lecturer in 2001. In 2008 he became Professor of Medicine and Consultant Physician in the Central Manchester University Teaching Hospitals and the University of Manchester. In 2014 he was appointed as Professor of Medicine at Weill Cornell Medicine and remains an honorary Professor of Medicine at the University of Manchester and visiting Professor of Medicine at Manchester Metropolitan University. He was appointed as the Organizational Official in November 2016 and as the Assistant Dean for Clinical Research at Weill Cornell Medicine-Qatar in February 2019.

His research focuses on the pathogenesis, assessment and treatment of diabetic and other peripheral neuropathies and central neurodegenerative disorders. Over ~20 years he has pioneered the use of corneal confocal microscopy, a non-invasive ophthalmic instrument, to quantify neurodegeneration in diabetic and other peripheral neuropathies and more recently in patients with Multiple Sclerosis, Parkinson’s disease, Stroke, Dementia, Autism and long-COVID.

Based on an independent analysis by Expertscape, the world’s leading index of academic achievement and expertise in healthcare of his published research between 2012 and 2022, he was rankedthe 2nd and 7^th most influential researcher on diabetes complications in the UK and the world,respectively. He has published ~450 peer reviewed papers and has Web of Science h-index=55; Google Scholar h-index=88; i10-index=328.

He was the President of Neurodiab (the diabetic neuropathy study group of the EASD) from 2009-2012. He is the recipient of the prestigious 2019 Camillo Golgi Prize from the European Association for the Study of Diabetes and the Gulf Association for Endocrinology and Diabetes Gold Medal Prize for research in 2022. He is an associate editor for J of Diabetes Complications (2012-present), PLOS One (2016-present), BMC Neurology (2009-present) and Scientific Reports (2019-present).

Duality of Interest: None declared
Date: Spring 2023

Giuseppe Maltese is a consultant physician in diabetes and endocrinology at Epsom and St Helier University Hospitals and honorary clinical lecturer at King’s College London. Dr Maltese graduated with a distinction in medicine from the University of Messina. Having also trained in General and Geriatric Medicine, he has a special interest in the management of frailty in diabetes. During his PhD at Cincinnati Children’s Hospital Medical Center, USA, and during his specialty training at Guy’s and St Thomas’ NHS Foundation Trust, London, he studied biomarkers of ageing in diabetes, cardiovascular and renal disease. He has authored numerous publications in peer-reviewed journals.

His current clinical and research work focuses on the impact of multimorbidity and frailty on diabetes-related outcomes and the use of technology in older people with diabetes. In addition, he has been the lead author of the Italian version of the NHS document Language Matters in Diabetes. As a Fellow of the Higher Education Academy (FHEA), Dr Maltese is actively involved in the teaching and supervision of medical students from St George’s University and training of junior doctors, GPs and other healthcare professionals in Surrey. In 2021, he was appointed as one of 20 Diabetes UK Clinical Champions in the UK with a project aimed at improving diabetes care in long-term facilities. In 2022 he was elected Fellow of the Royal College of Physicians of London.

Duality of Interest: None declared
Date: Summer 2023

Gillian Manning initially qualified as a Clinical Physiologist in the 1970’s before moving into clinical research and then clinical education. Having gained her PhD in 1998 from the University of Nottingham (UoN) she later became an Associate Professor of Vascular Medicine at the UoN.

Dr Manning has an ongoing research interest in hypertension and cardiovascular disease, including diabetes. She has experience of undertaking commercial research, including studies in diabetes such as ADVANCE and CANVAS. She has also led her own research programmes in the field of hypertension.

With a long-standing interest in education and training, Dr Manning’s early work involved developing national training programmes for clinical physiologists. In 2003, she was part of the team that developed and launched a new 4-year Graduate Entry Medical (GEM) Programme and trained as a Problem-Based Learning Facilitator. In 2006, she gained an MSc in Medical Science (Clinical Education) awarded by the UoN, graduating with distinction. She held many posts in the UoN, including Director of Research Education, Examinations Officer, and Director of a new Postgraduate Certificate in Teaching, Learning and Assessment all within the in the School of GEM and Health. During a part-time secondment to the Department of Health and Health Education England, she led the development of undergraduate and postgraduate curricula across more than 50 healthcare science specialisms. Dr Manning continues to work part-time for NHS England within the Medical Associate Professions Programme. She has extensive experience of teaching and learning across medicine and other healthcare professional groups, including clinical skills, problem-based learning, small-group teaching and lecturing. Within the field of assessment she has experience of both summative and formative assessment design, including on-line assessment and quality assurance.

Dr Manning has published journal articles spanning clinical education; hypertension; ambulatory blood pressure monitoring, diabetes and vascular medicine. Her contributions to national and international scientific meetings include more than 50 oral or poster presentations. In March 2018 she was awarded the Chief Scientific Officer Healthcare Science Lifetime Achievement Award for services to Healthcare Science and Healthcare Science Education; in December 2019, Fellowship of the Academy for Healthcare Science (AHCS); in 2022 Fellowship of the National School of Healthcare Science in recognition of the  strategic advice, work, support and input to the formation, development and delivery of the remit of the School and in 2023 her contribution to healthcare science education was recognised by the award of an Education Fellowship of the AHCS.

She has worked as a Clinical Education Consultant for the EASD’s e-Learning platform since 2019 leading a range of major education development programmes and writing multiple choice questions.

Duality of Interest: None declared
Date: Autumn 2023

Sally Marshall (BSc MB ChB MD FRCP (G) FRCP (L)) undertook her medical training at the University of Glasgow. She is Professor Emerita, Newcastle University and previously Honorary Consultant Physician. 

Professor Marshalls’ research focus was in diabetic nephropathy, including genetics, cellular biology, natural history, links to cardiovascular disease and management.  She lead studies investigating the role of polymorphisms of cytoskeletal proteins in the development of nephropathy, using the Warren 3 DNA repository for type 1 diabetes; the increased thrombogenicity seen in diabetes, using the Baudimon chamber to assess ex vivo thrombogenicity and the response to antiplatelet therapy and studies relating expression of the pro-thrombotic phospholipid phosphatidylserine (PS) on the outer membrane of platelets to vascular risk. Her in vitro work explored the mechanisms stimulating expression of PS and differences between non-diabetic and diabetic patients and patients with and without renal disease. She has longstanding experience in undergraduate and postgraduate Medical Student and Biomedical Sciences teaching, training and assessment. She was Director of Newcastle University/Northern Deanery Integrated Academic Pathway 2013-2018.

She was NICE advisor on hypertension and renal disease in diabetes.  She served as Editor for Diabetic Medicine from 2005-2009 and was the Editor in Chief of Diabetologia until 2021. She was the founding Chair of the Management Committee for Diabetes UK Clinical Study Groups and the President of European Diabetic Nephropathy Study. Additionally Professor Marshall was a board member of the EASD.

Duality of Interest: None declared.
Date: Summer 2023

Elisabeth Mathiesen is Professor of Endocrinology, chief physician and associate professor in the faculty of health science, University of Copenhagen, Rigshospitalet, Denmark. She is also head of diabetes treatment at the Copenhagen Centre for Pregnant Women with Diabetes, working with gestational and pregestational diabetes.

Professor Mathiesen’ research focuses on pregnant women with type 1 and type 2 diabetes, focusing on prevention of pre-eclampsia, preterm delivery and stillbirth. Specifically, her research involves investigating the beneficial effects of strict metabolic control; the use of insulin analogues and continuous glucose monitoring in pregnancy; the risk of women with previous GDM developing diabetes and the metabolic syndrome; the risk to children of women with high glucose concentrations in the intrauterine environment due to diabetes during pregnancy, and the beneficial effect of treatment of pregnant women with kidney involvement with antihypertensive drugs as well as pre-eclampsia.

Professor Mathiesen has published more than 350 scientific papers and supervised 13 PhD students. She is a member of the European Association for the Study of Diabetes, the European Diabetes in Pregnancy Study Group, the European Diabetic Nephropathy Study Group, the Danish Endocrine Society, Danish Society of Internal Medicine and the Danish Society for Hypertension, Pre-existing Diabetes and Pregnancy.

Duality of Interest: None declared
Date: Summer 2023

Chantal Mathieu is Professor of Internal Medicine and Chair of Endocrinology at the University Hospital Gasthuisberg, Catholic University of Leuven (KU Leuven), Belgium. Professor Mathieu received her medical degree and PhD from KU Leuven, where she subsequently completed training in internal medicine and endocrinology.

Her clinical areas of interest include endocrinology, diabetes and the organisation of diabetes care. Her research activity is focused on the prevention of type 1 diabetes, effects of vitamin D on the immune system and diabetes, functioning of the insulin-producing beta cell, adjunct therapies in type 1 diabetes and novel glucose-lowering agents in type 1 and type 2 diabetes.

Professor Mathieu has authored and co-authored more than 400 peer-reviewed publications in international journals. She has served on the editorial boards of the Journal of Diabetes and its Complications (2012-14), Endocrinology (2013-19) and JSMBM (2013-), on the advisory boards of Diabetologia (2007-11), Lancet Diabetes Endocrinology (2019-) and was Associate Editor of Diabetologia from 2003-06. In 2013, she received the prestigious InBev-Baillet Latour Prize for Clinical Research for her pioneering research on the pathogenesis of type 1 diabetes. She presently co-ordinates the INNODIA project on prevention and intervention in type 1 diabetes in Europe.

Professor Mathieu was appointed Teacher of Trainees in Endocrinology in 1998 and has been a full professor at KU Leuven since 2002. In that time she has been programme director of Leuven’s Biomedical Sciences (2006-16), received the Best Teacher award every year between 2015 and 2018, and has supervised 18 PhD theses and over 10 masters theses.She is President of EASD and Vice President of EUDF since 2023.

Duality of Interest: Professor Mathieu has received research support/grants from Medtronic, Imcyse, Novo Nordisk, Sanofi and ActoBio Therapeutics. She has also received payments for membership of boards/advisory panels from Novo Nordisk, Sanofi, Merck Sharpe and Dohme Ltd., Eli Lilly and Company, Novartis, AstraZeneca, Boehringer Ingelheim, Roche, Medtronic, ActoBio Therapeutics, Pfizer, Imcyse, Insulet, Zealand Pharma, Avotres, Mannkind, Sandoz and Vertex together with speaker’s fees/ honoraria from Novo Nordisk, Sanofi, Eli Lilly & Company, Boehringer Ingelheim, Astra Zeneca and Novartis. 

Financial compensation for the activities above has been received by KU Leuven (University Hospital Gasthuisberg, Catholic University of Leuven (KU Leuven), Belgium).

Date: Autumn 2023

David Matthews trained at the University of Oxford (BA, BM, BCh, MA and DPhil). He is a Fellow of the Royal College of Physicians (FRCP) and Hon DM, Aristotle University (Honoris causa).

Professor Matthews has devoted his life to diabetes – combining clinical care, teaching and research. His studies have focused on type 2 diabetes, including insulin secretion and action, insulin resistance, mathematical modeling of insulin resistance and the analysis of pulsatile insulin (and other hormones, especially growth hormone) using time-series analysis. He has been part of, and led many trials in diabetes.

As well as having given many lectures worldwide, his medical teaching and assessment experience includes organising and running the MRCP Part 1 course at Central Middlesex Hospital and lectures on diabetes at the Oxford Medical School. He was Director of Medical Studies at Harris Manchester College (1996-2008) and instituted and directed the Robert Turner Post-graduate course (residential) at Oxford until 2019.

He was deputy co-ordinator and member of the Executive and Policy Advisory Committees of the UK Prospective Study of Diabetes (UKPDS) and founder member of the Oxford Health Alliance, a multiple stakeholder collaboration to address and prevent chronic illness. He was co-director (2005-2013) of the National Diabetes Research Network (URDRN), which was managed jointly by Imperial College London and Oxford University. He was co-chair of the CANVAS and CANVAS-R studies and Chair of the Steering committee of the VERIFY trial.

He raised the funding for, and oversaw the building of the Oxford Centre for Diabetes, Endocrinology and Metabolism (OCDEM), of which he was the first Chairman (1999-2013). Over the course of his career he has written more than 320 peer-reviewed publications (citations: 65,987 [July 2020]; H index: 72). He has also undertaken peer review for many top-ranking journals, including Diabetes, Diabetes Care, Diabetelogia and the Lancet, and was on the Editorial Board for Diabetic Medicine. He delivered the 2010 Banting lecture for Diabetes UK, for whom he also served as Chair of the Grants Committee. He is a past President of the EASD.

Duality of Interest: None declared
Date: Autumn 2022

Tatjana Milenkovic is a professor of internal medicine at the Medical Faculty in Skopje. She has worked at the Clinic of Endocrinology, Diabetes and Metabolic Diseases since 1985, where in 1995 she established the Department of Education of People with Diabetes – and she has been Head of the department ever since. She completed her specialty training in internal medicine 1991, a PhD in medical science in 1999, and sub speciality training in endocrinology in 2004. She has significantly improved her working experience and skills in the UK, Denmark and Italy.

She is a member of the European Association for the Study of Diabetes (EASD), American Diabetes Association (ADA) and a President elect of the Diabetes Education Study Group (DESG). She has been the President of Macedonian Diabetes Association since 2013, the President of the Macedonian Scientific Association of endocrinologists and diabetologists since 2014 and a member of the International Diabetes Federation (IDF) Europe board (2020-22). She is a member of ESE (European Society of Endocrinology) educational committee (2021-25).

She is engaged in education for patients and families with diabetes and also in designing and implementing a programme for certification of diabetes educators in Macedonia. In co-operation with the World Health Organisation (WHO), she has organised education in Macedonia for healthcare professionals dealing with diabetes. She has been an invited lecturer at several EASD Postgraduate Courses, where she has educated future diabetologists, both theoretically and practically, on education in the treatment of diabetes, proper nutrition and physical activity. She organised a similar course together with EASD in Macedonia.

As a full professor of internal medicine, she has been involved in undergraduate and postgraduate education at her country’s medical faculty since 2002.

Duality of Interest: None declared
Date: Autumn 2022

Shivani Misra is a consultant physician in diabetes and metabolic medicine at Imperial College Healthcare NHS Trust and an Honorary Senior Clinical Lecturer within Imperial College London, UK. Dr Misra leads a portfolio of studies that investigate the genetics, epidemiology, classification and treatment of early-onset type 2 diabetes, defined as a diagnosis of type 2 diabetes in childhood or early-adulthood (<40 years).

Dr Misra was awarded a Future Leaders Mentorship Award from the European Federation for the Study of Diabetes (2017) and in 2021 was awarded a Quality in Care (QiC) award from NHS England for contributions to diabetes research and services. She is actively involved in medical education, including teaching both undergraduate and postgraduate students on diabetes-related topics and supervision of masters and doctoral students on projects related to diabetes.

Duality of Interest: Dr Misra has received research support / grants from, DexCom and is a trustee (no financial replacement) for the Diabetes Research & Wellness Foundation.

Date: Winter 2022

Hindrik Mulder is Professor of Metabolism at Lund University, Sweden, where he completed a PhD in 1997 and established his own research group after being appointed Associate Professor by the Swedish Research Council. After his PhD, Professor Mulder was awarded a Juvenile Diabetes Research Foundation (JDRF) postdoctoral fellowship at the Diabetes Centre at Southwestern Medical School in Dallas, USA. He currently holds an outpatient clinic for patients with diabetes at the Department of Endocrinology, Skåne University Hospital, Sweden.

His research focuses on the disease mechanisms in insulin-secreting beta cells associated with type 2 diabetes. He has developed metabolomics and imaging techniques to explore metabolic events in beta cells and islets. More recently, he has elucidated how genetic variants associated with type 2 diabetes contribute to disease mechanisms.

Professor Mulder has taught extensively at the undergraduate and graduate level at the Medical and Natural Science faculties at Lund University; this has involved lectures and group tuition. Mulder is the author of a textbook on diabetes in Swedish. He has supervised eight PhD students and 26 postdoctoral fellows. Professor Mulder has been Deputy Head of Department of Experimental Medical Science. He is currently a member of the Lund University Diabetes Centre (LUDC) management group and Vice Co-ordinator and board member of EXODIAB, a national strategic research area in diabetes.

Professor Mulder was a appointed editor-in-chief of Diabetologia in January 2021. Prior to that, he served as Senior and European editor of The Journal of Endocrinology for over 10 years. He received the Nordic Prize for Outstanding Young Diabetes Investigator, the Carl Tesdorpf Award for his research contributions and the Anna-Greta Crafoord Prize.

Duality of Interest: None declared

Date: Autumn 2022

Eoin Noctor is a Consultant Endocrinologist and Adjunct Senior Lecturer with the University of Limerick Hospitals Group/University of Limerick Graduate Entry Medical School.

Dr Noctor is a graduate of University College Dublin and became a member of the Royal College of Physicians in 2007. After completing his specialist training in Endocrinology and Diabetes Mellitus in Ireland in 2013, he took up a post as a Chief Physician at Steno Diabetes Center in Denmark, where he led the international medical education team, working with local organisations in low- and middle-income countries to design and deliver educational and training programmes in diabetes management.

His research interests include the long-term impact of gestational diabetes (in which he was awarded his doctoral thesis), prevention of type 2 diabetes, methods of provision of diabetes care in different populations, and the training of healthcare professionals in diabetes management. He continues to publish in the field of diabetes and is active in clinical research in diabetes in pregnancy, including serving on the data and safety monitoring board of the multicentre EMERGE trial on metformin.

He holds a postgraduate diploma in clinical medical education from the National University of Ireland, Galway, where he is involved in the diabetes care distance-learning programme for primary care healthcare professionals and is a member of the Postgraduate Education committee for the European Association for the Study of Diabetes (EASD). He is also a member of the American Diabetes Association, the European Society of Endocrinology and the Irish Endocrine Society.

Duality of Interest: None declared
Date: Summer 2023

Kalliopi Pafili underwent medical training at the University Hospital of Alexandroupolis, Greece, graduating in 2013 with honours. She completed her doctoral thesis under the supervision of Professor Nikolaos Papanas in 2018 with honours. She has then worked as assistant physician in the Department of Internal Medicine of the Medical University of Alexandroupolis, Greece and as clinician scientist in the research group Energy Metabolism, headed by Professor Michael Roden at the Institute for Clinical Diabetology of the German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University of Düsseldorf, Germany. Since 2022, she is now working as assistant physician in the Department of Endocrinology and Diabetology (Director Professor Roden) of the Medical Faculty and University Hospital of the Heinrich-Heine University in Düsseldorf, Germany. Her research has led to 47 publications listed in PubMed and aims to gain a better understanding of the mechanisms underlying the pathogenesis and progression of insulin resistance and non-alcoholic fatty liver disease (NAFLD) in humans. This work currently focusses on hepatic and adipose tissue energy metabolism, glucose and lipid fluxes. Dr. Pafili is also interested in clinical education and teaching medical students and junior colleagues in diabetes mellitus and other endocrinological disorders.

Duality of Interest: None declared
Date: Autumn 2022

François Pattou is Professor of General Surgery in the Faculty of Medicine at Lille University, France, and Head of the Department of General and Endocrine at Lille University Hospital.

He leads a research group at the University of Lille, INSERM U1190, devoted to the clinical development of biotherapies for treating diabetes, and is a founding member of the LABEX European Genomic Institute for Diabetes (EGID). Professor Pattou’s research is devoted to the surgical treatment of endocrine and metabolic diseases and focuses on cell therapy for type 1 diabetes and metabolic surgery for type 2 diabetes. He is also the principal investigator of several ongoing clinical trials of islet cell transplantation and metabolic surgery. He has authored more than 250 papers in peer-reviewed journals.

The recipient of numerous research grants from national and international institutions (European Commission, Innovative Medicine Initiative, Agence Nationale de la Recherche, Juvenile Diabetes Research Foundation, Foundation Francophone pour le recherche sur le diabète), Professor Pattou has been awarded several prizes (National Academy of Medicine, Rachmine Levine scientific achievement award, Matmut award). He is a member of the European Surgical Association  and is President of the Association Francophone de Chirurgie Endocrinienne. He is regularly invited to give lectures at international conferences and teaching courses such as the EASD e-Learning programme.

Duality of Interest: Professor Pattou has received speaker’s fees/honoraria from Novo Nordisk, Medtronic and Ehthicon. He has also received payments for membership of boards/advisory panels from Novo Nordisk, Medtronic and Ehthicon.

Date: Summer 2023

Gianluca Perseghin is Professor of Endocrinology in the Department of Medicine and Surgery and Director of the School of Endocrinology and Metabolic Diseases at the Università degli Studi di Milano Bicocca, Italy. He is also Director of the Department of Internal Medicine and Rehabilitation and unit manager of the Department of Endocrinology at the Policlinico di Monza. He graduated with honours in medicine and surgery from the University of Milan in 1990 and began his research training in the field of endocrinology and metabolic diseases at the Scientific Institute H San Raffaele, Milan. He subsequently undertook his post-doctoral fellowship at Yale University School of Medicine, USA.

On his return from Yale at the end of the 1990s, he developed his research activity at the Scientific Institute H San Raffaele, focusing on the use of in vivo methods in humans for the study of metabolism in various organs and tissues to determine their contribution to energy homeostasis. In 2008 he was made Associate Professor of Medical Technical Sciences at the Department of Biomedical Sciences for Health of the University of Milan and continues to carry out research on the homeostasis of in vivo energy metabolism in humans in the course of his consultancy activity at the Policlinico di Monza. His areas of research interest include insulin action and secretion in physiology and pathology; insulin resistance-hyperinsulinaemia interaction and its impact on cardiovascular risk, body composition, fat distribution and ectopic fat, and the use of the latest state of the art techniques for the study of energy metabolism. In particular, he has focused his interest on ectopic fat accumulation within the liver and its relationship with energy metabolism. His work includes seminal reporting on the cardiovascular metabolic features of subjects with NAFLD.

Professor Perseghin has contributed to all of the leading diabetes journals over the years, both as an author (over 150 original papers, H1: 41 citations; 7500 in Scopus or H1: 48 and over 11,500 in Google Scholar) and as a referee, and has been a member of the editorial board for, among others, the Journal of Clinical Endocrinology, Diabetes Care, The American Journal of Physiology, Endocrinology and Metabolism. He has also been Associate Editor of Nutrition, Metabolism and Cardiovascular Disease and Diabetic Medicine.

Over the course of his career he has been an invited speaker at many national and international conferences and is the recipient of numerous awards, including the GB Morgagni Prize Silver Medal for Young European Scientists; the National Prize in the Field of Research of the Italian Diabetes Society (SID) and, in 2008, the Young Investigator Novartis Prize in Diabetes, He was recipient of the EASD’s Minkowski Prize in 2009).

Duality of Interest: Professor Perseghin has received speaker’s fees/honoraria from AstraZeneca, Boehringer Ingelheim, Eli Lilly & Company, Novo Nordisk, PicDare and Sanofi. He has also received payments for membership of boards/advisory panels from AstraZeneca; Boehringer Ingelheim; Eli Lilly; Merck; Novo Nordisk; Novartis; Pfizer; Sanofi.

Date: Autumn 2022

Frederik Persson is a chief physician and senior researcher at the Steno Diabetes Center Copenhagen in the research group led by Professor Peter Rossing, which has a long-standing interest in the area of diabetic complications.

For the past 17 years, diabetic nephropathy and diabetic complications have been his main areas of interest. His research has spanned epidemiology, biomarkers and small explorative studies to participation in, and post-hoc analyses of, large randomised controlled trials. In particular, he has contributed to clinical research in relation to a new treatment concept, renin inhibition, exploring the potential for further renoprotection in patients with type 2 diabetes. This was also the topic of his doctoral thesis, accepted and defended in 2013 at the University of Copenhagen.

In addition to his clinical research, he spends 50% of his time in the outpatient clinic at Steno Diabetes Center Copenhagen, with a focus on development of the care and prevention of complications in people with diabetes. He has lectured on post-graduate courses and symposia in India, China, the Middle East and South America.

Duality of Interest: Dr Perrson has received research support / grants from Astra Zeneca, Novo Nordisk and Boehringer Ingelheim and speakers honorarium / fees from Astra Zeneca, Novo Nordisk and Boehringer Ingelheim. He has also received payments for consultancy from Astra Zeneca, Novo Nordisk and Boehringer Ingelheim
Date: Summer 2023

Dimitri Pournaras is a Consultant in Upper Gastrointestinal and Bariatric Surgery at the North Bristol NHS Trust, UK. He graduated from the Aristotle University of Thessaloniki, Greece, undertook all his postgraduate training in the UK and completed a PhD in the Department of Investigative Medicine, Hammersmith Hospital, Imperial College London. Following this, he underwent training in laparoscopic oesophagogastric surgery in Cambridge and Norwich, UK. He was granted a Bariatric and Metabolic Surgery Fellowship by the Royal College of Surgeons in Musgrove Park Hospital, Taunton, after which he was appointed to his current position in Bristol.

Dr Pournaras’ clinical interests include surgical treatment of obesity, diabetes as part of multimodal care and laparoscopic upper gastrointestinal surgery. His research interests include outcomes of bariatric and metabolic surgery beyond weight loss, with a focus on obesity associated morbidity and cardiovascular risk. His research activity also includes investigating how bariatric/metabolic surgery changes the way the gut talks to the brain. Dr Pournaras is the inaugural British Obesity and Metabolic Surgery Society/Royal College of Surgeons of England bariatric Surgical Specialty Lead and is committed to high quality, collaborative, patient centred research with the objective to improve obesity care.

He is on the editorial board of the international peer-reviewed journals Obesity Surgery and Clinical Obesity and has authored more than 100 peer-reviewed publications, including articles in The Lancet, The Annals of Surgery, The British Journal of Surgery and The BMJ. Dr Pournaras delivers more than 10 invited international lectures on a yearly basis.

Duality of Interest: Dr Pournaras has received research support / grants from Medtronic, speaker’s fees/honoraria from Johnson & Johnson and Novo Nordisk. He has also received payments for membership of boards/advisory panels from Johnson & Johnson and consultancy fees from Johnson & Johnson and Novo Nordisk.

Date: Spring 2023

Stefano Del Prato is a retired Professor of Endocrinology and Metabolism at the School of Medicine, University of Pisa and Chief of the Section of Diabetes of the Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy. Currently he is affiliate Professor of Medicine at the Interdisciplinary Research Center “Health Science” of the Sant’Anna School of Advanced Studies in Pisa. He graduated MD cum laude from the University of Padova and undertook post-graduate specialisation in both Endocrinology and Internal Medicine.

Professor Del Prato’s research interests have always been concerned with diabetes and, in particular, the physiopathology and therapy of type 2 diabetes and insulin resistance syndrome.

He is a member of many societies and associations, including the European Association for the Study of Diabetes (EASD), the American Diabetes Association, and the International Diabetes Federation. He acts as referee for all major journals and has served on the Editorial Boards for the Journal of Clinical Endocrinology and Metabolism, Diabetes Care, and the Journal of Diabetes and Its Complications, Journal of Endocrinological Investigation, and Diabetes & Vascular Disease Research.

Professor Del Prato has published over 531 articles in national and international journals and has been awarded several honours, including the Prize of the Italian Society of Diabetology for outstanding scientific activity. Having served as Vice-President of the EASD from 2011-14, he became President from 2020-2022. He also served as President of Italian Society of Diabetology (2012-14) and as Chairman of the European Foundation for the Study of Diabetes (2015-19) and is currently president of the European Diabetes Forum.

Duality of Interest: Professor Del Prato has received research support/grants from Astra Zeneca and Boehringer Ingelheim and speaker’s fees/honoraria from Astra Zeneca, Berlin Chemie, Boehringer Ingelheim, Eli Lilly and Co, Menarini, Novo Nordisk and Sanofi. He has also received payments for membership of boards/advisory panels from Abbott, Amarin, Applied Therapeutics, Astra Zeneca, Bayer, Eli Lilly & Co, Hengrui Pharmaceuticals, Novo Nordisk, Sanofi and Sun Pharmaceuticals together with consultancy payments from Menarini.

Date: Autumn 2023

Amar Puttanna is a diabetes and endocrine consultant in the West Midlands. He is particularly interested in education, having won teaching awards from the University of Birmingham and the Royal College of Physicians of Edinburgh. He currently sits on the MRCP Part 1 examining board. In 2018, he received an Excellence in Patient Care Award from the Royal College of Physicians for his contribution to the profession.

He is involved in writing guidelines, including those on older adults with diabetes with the Joint British Diabetes Societies (JBDS) and guidelines/patient leaflets on diabetes and dementia. He has also worked on local guidelines for type 2 diabetes management, including areas such as cardiovascular disease and frailty.

He sits on the editorial board for the British Journal of Cardiology, is involved in a nationwide education programme for care homes. He has been an invited speaker at national and international conferences.

Dr Puttanna’s interests are in cardiovascular disease, diabetes management in older adults including cognitive impairment and translating research into clinical practice, sustainability in diabetes care and he is active on social media (@AmarPut). His work in cognitive impairment (DIADEM project) won a Quality in Care award in 2018.

NOTE: Since this biography was written, Dr Puttanna has become National Advisor for Clinical Engagement for the pharmaceutical company Sanofi. As of January 2022, he will no longer be setting assessments for the EASD e-Learning platform.

Duality of Interest: Dr Puttanna has been an employee of Sanofi since 2022 and has received speaker’s fees/honoraria from Novo Nordisk and Astra Zeneca.
Date: Summer 2023

João Filipe Raposo (MD, PhD) is a guest assistant professor of public health in the Faculty of Medicine at NOVA Medical School in Lisbon, where he has worked since 2011, lecturing in Introduction to Medicine and Diabetology. He graduated in medicine in 1988 from the University of Lisbon and received his PhD in Medicine-Endocrinology in 2004 at the New University of Lisbon with a thesis on calcium physiology mathematical models. He carried out his endocrinology residency in the Portuguese Cancer Institute from 1991 to 1997.

He is also the clinical director of the Association for the Protection of Diabetics of Portugal (APDP), which supports people with diabetes, their families and caregivers, providing quality healthcare and educational services. It also collaborates in the development of public and social policies focused on the rights and needs of people with diabetes and develops research projects, in partnership with national and international organisations, with a view to improving the treatment and cure of diabetes. The work of the APDP was recognised by the World Health Organisation (WHO) as an example of good practice during the COVID-19 pandemic.

Professor Raposo is also the president of the Portuguese Society of Diabetology (SPD), a role he has held since 2020, as well as a consultant to the WHO on diabetes and non-communicable diseases.

He has published numerous papers, including ‘Intensive monitoring of adverse drug events associated with the use of new glucose-lowering drugs: results from an inception cohort study’ in Portugalin 2020 (Diabetic Medicine) and ‘Monogenic diabetes characteristics in a transnational multicenter study from Mediterranean countries’ in 2021 (Diabetes Research and Clinical Practice).

Duality of Interest: None declared
Date: Autumn 2022

Erik Renström is Vice-Chancellor of Lund University, Sweden, where he oversees university activities and leads the University Board. He is professor of Experimental Endocrinology and leading researcher in hormone secretion and translational diabetes research. He graduated from the Institute of Medicine at the University of Gothenburg, Sweden in 1990 and has since held several positions at Lund University and the Swedish Research Council.

Professor Renström’s research focuses on diabetes, particularly the insulin-producing beta cells in the pancreas. His research group primarily investigates beta cells by electrophysiology, live imaging and super-resolution microscopy. The group has a particular interest in genetic or environmental factors that accelerate ageing and reactions in the beta cell that increase the risk of diabetes. He has conducted diabetes research in Lund and Gothenburg, spent time completing postdoctoral studies in the UK and worked at Novo Nordisk A/S. He has previously served as Vice Co-ordinator of the Linnaeus grant for diabetes research at Lund University,  as co-ordinator for EXODIAB, as a Board Member for Clinical Research Center, Malmö and Department of Clinical Sciences, Malmö and as Dean of the Faculty of Medicine at Lund University.

Professor Renström has published over 70 articles in peer-reviewed journals. He has participated as an invited speaker at numerous conferences, including the American Diabetes Association’s (ADA) Scientific Sessions, and has been the recipient of the Paul Langerhans Award and awards bestowed by Lund University and the Swedish Research Council.

Duality of Interest: None declared
Date: Spring 2023

Michael Rickels is a Professor of Medicine and Director for Clinical Science in the Division of Endocrinology, Diabetes and Metabolism at the Hospital of the University of Pennsylvania in Philadelphia, USA. He first graduated from the University of Pennsylvania Perelman School of Medicine where he completed his residency training in internal medicine and postdoctoral fellowship training in endocrinology and currently works as the Willard and Rhoda Ware Professor in Diabetes and Metabolic Diseases. He specialises in diagnosis and treatment of diabetes, hypoglycaemia disorders and general endocrinologic problems. His clinical interests include pancreas and islet allotransplantation as therapies for type 1 diabetes, and islet autotransplantation for patients undergoing pancreatectomy.

His research areas of expertise include the pathogenesis of various forms of diabetes, the in vivo mechanisms of new diabetes treatments, and islet function and replacement in type 1 diabetes and pancreatogenic forms of diabetes. He has authored over 160 papers in his career and conducts patient-oriented diabetes research, often using studies that involve methodologies for quantifying insulin and incretin secretion, insulin sensitivity and glucose counterregulatory responses to hypoglycaemia. Presently, his work in type 1 diabetes is focused on novel approaches to the prevention or correction of hypoglycaemia, including by closed-loop technology and islet replacement approaches for patients with difficult to control type 1 and pancreatogenic diabetes.

Professor Rickels’ work has been continuously funded by the USA’s National Institutes of Health (NIH) where he has served on the Clinical and Integrative Diabetes and Obesity Study Section and on the Restore Insulin Secretion Data and Safety Monitoring Board and chaired the metabolics study subcommittee for the Clinical Islet Transplantation Consortium and has chaired the publications and presentations committee for the Collaborative Islet Transplant Registry. Professor Rickels recently served as an elected councilor for the International Pancreas and Islet Transplant Association and on the Planning Committee for the American Diabetes Association (ADA), where he was responsible for developing programme content for islet biology and insulin secretion. He is currently the Medical Director of the Pancreatic Islet Cell Transplant Program at the Hospital of the University of Pennsylvania, and Director of the Translational Research Program for the Institute for Diabetes, Obesity and Metabolism at the University of Pennsylvania Perelman School of Medicine.

Duality of Interest: None declared

Date: Autumn 2022

Michael Roden is Chair and Full Professor of Internal Medicine, Endocrinology and Metabolic Diseases at Heinrich-Heine University, Director of the Department of Endocrinology and Diabetology at University Hospital Düsseldorf, and has been Chief Scientific Executive Officer of the German Diabetes Center (DDZ) since 2008.

Since 2017, he has been the Speaker of the Committee Medicine of the Scientific Commission of the German Council of Science and Humanities, which advises the President and the Federal Government of Germany. He is on the Board of Speakers of the German Centers for Diabetes Research (DZD). Previously, he served as the Head of the Medical Department of the Teaching Hospital of Medical University of Vienna, Hanusch Hospital and as Associate Professor at the Medical University of Vienna and the General Hospital of Vienna, Austria. From 1995-1996, he was also Max-Kade Fellow at Yale University, New Haven, USA.

His research interests include the energy metabolism of people with or without diabetes mellitus and obesity. His groundbreaking findings on the effects of fat in muscle tissue have contributed significantly to the elucidation of fat-induced insulin resistance in humans. In recent years, his work has focused on the function of mitochondria using new non-invasive methods, such as magnetic resonance spectroscopy. He demonstrated how mitochondrial function influences the course of diabetes complications, such as non-alcoholic fatty liver disease (NAFLD). Most recently, he validated the concept of diabetes subgroups/subtypes and their relevance for specific diabetes-related complications. His research activities have resulted in more than 600 peer-reviewed papers in journals, such as the New England Journal of Medicine, Nature, Nature Genetics, Lancet Diabetes and Endocrinology, Cell Metabolism and the Journal of Clinical Investigation.

He currently serves on editorial boards for a number of journals, including Molecular Metabolism and Current Diabetes Reports. He has received several awards, including the International Novartis award (2004), the European Society for Clinical Investigation award (2006), the Oskar-Minkowski Prize by EASD (2006), the Somogyi award by the Hungarian Diabetes Association (2014) and the GB Morgagni Prize – Gold Medal Career Achievement (2018) awards. He is also a recipient of the German Diabetes Society’s most prestigious award, the Paul Langerhans medal (2017). He has been awarded honorary doctorates by the Medical School of the National and Kapodistrian University of Athens and by the Medical Faculty of the University of Belgrade. Professor Roden has been President of the Central European Diabetes Association and Austrian Diabetes Association, Honorary Treasurer and Executive Committee member of the EASD and is currently the Chairman of the EFSD.

Duality of Interest:
Professor Roden has received research support/grants from Boehringer Ingelheim, Nutricia/Danone, Novo Nordisk and Sanofi US and speaker’s fees/honoraria from Boehringer Ingelheim, Novo Nordisk, ProSciento Inc and Sanofi. He has also received consultancy payments from Eli Lilly and Company, Fishawack Group, Kenes Group, Target RWE and Sanofi US.  

Date: Autumn 2022

Peter Rossing is a clinician researcher whose work is devoted to complications in diabetes, with a particular focus on renal and cardiovascular complications. He obtained a specialist degree in internal medicine and endocrinology in 2004. Since 2007 he has been a chief physician and manager of the Steno Diabetes Center Copenhagen, Denmark, a research team dedicated to the research of micro- and macrovascular complications of diabetes. In 2012, he was appointed as a Professor in Diabetic Angiopathy at the University of Copenhagen. He is involved in multiple postgraduate courses in practical diabetology and diabetes research. Professor Rossing received the Minkowski prize in 2005 and the Golgi prize in 2016 – both from the EASD – and the E Bierman award from the American Diabetes Association (ADA). He is a past president of the Danish Endocrine Society and the European Diabetic Nephropathy Study group, and chairman of the Danish National Diabetes Registry.

Duality of Interest: Professor Rossing has received research support/grants from Novo Nordisk and speaker’s fees/honoraria from AstraZeneca, Bayer, Eli Lilly and Novo Nordisk. He has also received payments for membership of boards/advisory panels from AstraZeneca, Bayer, Boehringer Ingelheim, Novo Nordisk and Sanofi and has stocks/shares/directorship with Novo Nordisk.

Date: Autumn 2023

Naveed Sattar graduated in Medicine from the University of Glasgow, Scotland, in 1990, where he was also awarded his PhD in 1998. In 2005, he was appointed Professor of Metabolic Medicine at the Institute of Cardiovascular and Medical Sciences (now called School of Cardiovascular and Metabolic Health). He is also an Honorary Consultant in Metabolic Medicine at the Glasgow Royal Infirmary, where he co-leads a cardiovascular prevention clinic. 

Professor Sattar’s research focuses on prevention and management of diabetes, obesity and cardiovascular disease. He is currently involved in several lifestyle and drug trials in diabetes and cardiovascular disease (including cardiovascular outcome trials) and leads on biomarker initiatives in other outcome trials.  He is also involved in several COVID-19-related projects.

Many of Professor Sattar’s findings have been incorporated into clinical guidelines and he has served on national and international guideline committees, including: the European Society of Cardiology (ESC) Task Force to develop 2023 guidelines on diabetes and cardiovascular diseases (CVD); Joint British Societies guidelines on prevention of CVD in clinical practice; SIGN obesity and CVD prevention guidelines (as Chair); and European CVD prevention guidelines. He is one of the world’s most cited academics (in the top 1% of the field in clinical medicine) and has authored or co-authored over 1000 published papers, with over 190,000 citations (Google Scholar, March 2023). He is on the editorial board for BMC Medicine and is an Associate Editor for Diabetes Care.

Professor Sattar has spoken at numerous meetings in the UK and globally and has been the recipient of several prizes for his research. These include the Banting Memorial Lecture in 2023, the Rank Nutrition Lecture in 2018, the Minkowski Award Lecture in 2011, the Dorothy Hodgkin Lecture, the John French Lecture and the RD Lawrence Lecture. He presented the prestigious Camillo Golgi Prize lecture at the European Association for the Study of Diabetes (EASD) annual meeting in 2020. In 2016, he was elected a fellow of the Academy of Medical Sciences. He is also a Fellow of the Royal College of Pathologists, the Royal College of Physicians and Surgeons of Glasgow and the Royal Society of Edinburgh.  He has supervised 16 successful MDs/PhDs, including one awarded the Bellahouston Prize for the best thesis in medicine over the year.  He has also led or developed training courses for under- and postgraduate students and contributes to teaching at multiple levels.

Duality of Interest: Professor Sattar has received research support / grants from Astra Zeneca, Boehringer Ingelheim, Novartis and Roche Diagnostics and speaker’s fees/honoraria from Astra Zeneca, Boehringer Ingelheim, Eli Lilly and Novo Nordisk. He has also received payments for membership of boards/advisory panels from Amgen, Astra Zeneca, Boehringer Ingelheim, Eli Lilly, Novartis, Novo Nordisk, Pfizer and Roche Diagnostics together with consultancy fees from Astra Zeneca, Boehringer Ingelheim, Eli Lilly, and Novo Nordisk. 

Date: Spring 2023

Hanne Scholz (MSc, PhD) is Senior Researcher and Head of the Islet Isolation Facility at the Oslo University Hospital, University of Oslo, Norway. She holds a Bachelor Degree in Bioengineering from Bergen College of Engineering (1994), an MSc in Human Physiology from the Faculty of Mathematics and Natural Sciences (2000) from the University of Oslo, and a doctoral degree from the Faculty of Medicine, Institute of Clinical Medicine (2006).

Dr Scholz leads a significant research programme within the Department of Transplantation at the Institute for Surgical Research at the University of Oslo, aiming to improve and optimise islet isolation, beta cell replacement therapies and patient outcomes. The Scholz lab has led to multiple publications involving regenerative medicine projects, such as developing new cellular therapies for diabetes using stem cells and 3D bio-printing biomimetic pancreatic islets. Her research programme is highly multidisciplinary and comprises clinicians, transplant surgeon, technicians, postdoctoral researchers and students in different disciplines. In addition, the Scholz group is part of the Hybrid Technology Hub, a Centre of Excellence at the University of Oslo, which aims to develop ‘organ on a chip’ platforms of functional metabolic human tissue.

She has been published in numerous leading journals relating to diabetes and cell biology (1465 citations; H index, 23), including Diabetes, Diabetologia, Current Diabetes Reports, Cell Transplantation, Stem Cell Reviews and Reports, Frontiers in Cell and Developmental Biology, Transplantation International, Circulation and the Journal of Clinical Endocrinology and Metabolism.

Dr Scholz is an active board member of the Nordic Network for Clinical Islet Transplantation, a member of the Oslo Diabetes Research Centre, and a Councilor of the International Pancreas and Islet Transplantation Association (IPITA – 2017-2021) and the European Society of Organ Transplantation (ESOT – 2019-2023).

Samuel Seidu (MBChB, PGCME, MSc, MD, FRCGP, FRCP (Edin)) is Clinical Professor in Primary Care Diabetes and Cardio-metabolic Medicine at the University of Leicester, UK. He is currently the vice-chair for Research for Primary Care Diabetes Europe (PCDE). He is a board member of the Primary Care Diabetes Society of UK and is also currently a Clinical Lead and mentor for diabetes in the Leicester, Leicestershire and Rutland Integrated Care System. In 2021, he was named the most outstanding early career researcher by the Royal College of General Practitioners. He is a practicing Leicester City General Practitioner, a Partner, lead undergraduate tutor and GP trainer at the Hockley Farm Medical Practice and an associate editor of the Primary Care Diabetes journal.

His current research centres on (i) medication safety in diabetes and cardiometabolic diseases in the elderly population; (ii) quality improvement in diabetes care in primary care settings and (iii) addressing health inequalities in diabetes care. He is also working in the area of therapeutic inertia in people with diabetes to understand the causes, outcomes, and possible solutions.

Duality of Interest: Dr Seidu has received research support/grants from AstraZeneca, Janssen, Novo Nordisk, Servier, Sanofi and Takeda and speaker’s fees/honoraria from Abbot, Amgen, AstraZeneca, Eli Lilly, Janssen, MSD, Napp, Novo Nordisk, Sanofi and Takeda. He has also received payments for membership of boards/advisory panels from Abbot, Novartis, Janssen and Napp.

Date: Autumn 2022

Dinesh Selvarajah is Senior Lecturer in Diabetes at the University of Sheffield, UK, and Honorary Consultant Physician at Sheffield Teaching Hospitals NHS Foundation Trust. He qualified as a doctor at the University of Sheffield and trained in diabetes and diabetic neuropathy under Professor Solomon Tesfaye.

Dr Selvarajah’s research interests thus far have been chiefly in clinical studies applying modern magnetic resonance (MR) neuroimaging techniques in diabetic neuropathy. His skills in the field of clinical neuropathy and neuroimaging establish him as a researcher with a unique range of expertise within the field of diabetes research. His research projects also include epidemiology, risk factors, pathogenesis and treatment of diabetic neuropathy and neuropathic pain. He has received research funding from the European Foundation for the Study of Diabetes and the National Institute of Health Research (NIHR). He has international leadership roles, including Secretary of NEURODIAB (2015 to 2021) and Diabetes UK Clinical Study Group on Inpatient Diabetes. He was awarded the prestigious Dr Jeff Wadsworth-Battele Scholarship (2022) in Neuroscience, Engineering and Computer Science to attend the Stanford Neuroscience and Pain Lab at Stanford University (California, USA) to develop expertise in machine learning and data science, the Goran Sundquist Prize for Young Clinical Investigator of the Year (2012), first prize FinnDIANE research prize (2013) and first prize at the 5th NeupSIG International Congress on Neuropathic Pain (2015).

Duality of Interest: None declared

Date: Winter 2022

Inass Shaltout is Professor of Internal Medicine and Diabetes at the faculty of Medicine, Cairo University, Egypt. She has also worked as a Consultant at the New Kasr Al Eini Teaching Hospital and as chairman of the Internal Medicine Department, Faculty of Medicine, Cairo University.

Professor Shaltout’s research interests include the treatment of type 2 diabetes and the management of fasting during Ramadan for people with diabetes and she has supervised more than 30 postgraduate MSc and MD theses, Egypt. She was a co-author of the 2016 and 2021 publications Diabetes and Ramadan: Practical Guidelines, published by the International Diabetes Federation (IDF) in collaboration with the Diabetes and Ramadan (DAR) International Alliance.

She is currently the president of the Arabic Association of Diabetes and Metabolism and a member of the European Association for the Study of Diabetes (EASD). She is also a member of the Egyptian Society of Internal Medicine, the Egyptian Society of Diabetes, Endocrine and Metabolism, the Egyptian Society of Nephrology, the Egyptian Group of Diabetes and the Egyptian Medical Association of Studying Obesity (EMASO). Her teaching experience includes working for five years as an honorary lecturer on the Diabetes Diploma at Cardiff University, UK. She has served as a peer reviewer for many medical journals, including Diabetes Research and Clinical Practice and the International Journal of Clinical Practice.

Duality of Interest: None declared
Date: Spring 2023

Frank Snoek is Professor Emeritus of Medical Psychology at the Amsterdam University Medical Centers in Amsterdam, the Netherlands. He graduated from the University of Amsterdam in Clinical Psychology and received his PhD from the Faculty of Medicine, Vrije Universiteit Amsterdam. In 2004 he was the first full professor of medical psychology in the Netherlands appointed with a specialisation in psychosocial diabetology.

Professor Snoek’s clinical areas of interest include behavioural diabetes, diabetes self-management and mental health; his research emphasises the importance of furthering psychological needs assessment and diabetes-specific interventions in diabetes care. He founded and leads an outpatient tertiary clinic at the Amsterdam UMC offering a specialised service for people with diabetes and mental health problems (‘Diabetes Mentaal’). He and his team have developed and validated a range of psychological assessment tools and interventions for people with diabetes, including internet/mobile-based programmes. His current research projects focus on innovative applications, including Ecological Momentary Assessments (EMA) and a self-guided web-based app for enhancing mental vitality in type 1 diabetes. 

He has authored and co-authored various book chapters, co-edited two handbooks and published over 280 papers in peer-reviewed journals. He is on the editorial boards of Diabetes Research and Clinical Practice, Diabetes/Metabolism, Research and Reviews, Primary Diabetes Care, and Health Psychology Review and is Chief Speciality Editor for the section Diabetes Self-Management of Frontiers in Clinical Diabetes and Healthcare.

He is the founder and past chair of the EASD study group Psychosocial Aspects of Diabetes (PSAD). He is member of the IDF Global Guideline for Type 2 diabetes Task Force, has chaired the Dutch Guideline Committee for Depression in Diabetes of the Netherlands Diabetes Federation (NDF), and is the primary author of  the Dutch Guidelines for Medical Psychology in diabetes care. He is a member of the international panel of experts responsible for the first EASD/ADA Consensus statement for the management of type 1 diabetes.

Professor Snoek has a long-standing career as a lecturer and mentor for master and PhD students in the faculty of Medicine at the University of Amsterdam and VU University, and is guest lecturer for universities in the Netherlands and abroad. He is a frequent speaker at national and international diabetes and health psychology conferences. He has developed and delivered numerous symposia and training programmes on the topic of diabetes psychology for diabetes professionals. 

Professor Snoek has received several awards. In 2002 he received the Wolter Goeman Award from the Society for Medical Psychology (LVM) of the Netherlands Institute for Psychologists (NIP) and in 2008 was the first researcher to win the Diabetes Research Award for excellence from the Dutch Diabetes Research Foundation. In 2019 he was recipient of the Richard R Rubin Award from the American Diabetes Association (ADA) for his contributions to advancing behavioural diabetes research. In 2020, Professor Snoek received a high Royal Medal, Knight in the Order of the Dutch Lion (Ridder in de Orde van de Nederlandse Leeuw) for his leadership and outstanding work to advance the psychosocial aspects of diabetes.

Duality of Interest: Professor Snoek has received research support/grants from Sanofi and Novo Nordisk and speaker’s fees/honoraria from Lilly and Sanofi. He has also received payments for membership of boards/advisory panels from Lilly and Novo Nordisk and for other education activities from Lilly and Sanofi.

Date: Summer 2023

Anna Solini is Associate Professor in Internal Medicine at the University of Pisa, Italy, specialising in diabetes and metabolic diseases, gastroenterology and gerontology. She teaches and assesses undergraduate medical students and postdoctoral specialists in internal medicine, geriatrics and emergency medicine studying in the school of medicine at the university. Professor Solini’s research is mainly focused on vascular complications of diabetes (nephropathy and cardiovascular disease), hypertension in diabetes and mechanisms of systemic and tissue-specific inflammatory responses. She has been invited to speak at over 230 national and international meetings. She is a member of a range of national and international committees, including the Steno Research Collaboration committee. She has published 178 peer-reviewed journal articles and 20 book chapters, and serves as regular reviewer for several journals, including BMJ, DOM, JASN; Diabetes; Diabetologia; JCEM. She is also a member of the editorial board of several journals. Anna wonthe Parma Diabetes Medal for the best Italian young investigator from the Italian Society of Diabetology in 1997 and the Hyppocrates Prize from the Mediterranean Group for the Study of Diabetes in 1998.

Vincenza Spallone (MD, PhD) graduated in medicine and obtained her board certification in endocrinology and PhD in Endocrinological and Metabolic Sciences from the University of Rome La Sapienza, Italy. She was Assistant and Aggregate Professor of Endocrinology until 2018 in the Department of Systems Medicine, Faculty of Medicine and Surgery, University of Rome Tor Vergata, and since 2018 has had the honorary rank of ‘Docens Turris Virgatae’, teaching endocrinology at the degree courses of medicine, postgraduate and masters courses at the same university. Since 2019, she has been Honorary Professor at the State Institution V Danilevsky Institute for Endocrine Pathology Problems of the National Academy of Medical Sciences of Ukraine.

Professor Spallone has been a panel member and external examiner in PhD courses, and has been tutor and main supervisor of more than 45 final theses at degree and PhD level and of the research activities of numerous junior researchers.

Her own research is focused on diabetic neuropathy, in particular on the multifaceted expression of cardiovascular autonomic neuropathy (CAN), with pioneering studies on CAN impact on kidney function and blood pressure circadian rhythm and on standardisation of CAN testing, and on the epidemiology, clinical consequences and diagnosis of painful diabetic neuropathy with validation of DN4. Her research activities have resulted in more than 388 published works (articles, chapters, books, and abstracts) in journals such as Diabetes Care, Diabetologia, Diabetes, Clinical Science, Journal of Neurology Neurosurgery Psychiatry, Nephrology Dialysis and Transplantation, Pain, and Diabetes and Metabolism.

Professor Spallone has been a principal Investigator in 20 university-funded research projects and international clinical trials. She was the winner of the Valsalva Lecture Award of the Italian Society for Neurovegetative Research.

Professor Spallone is the present Chair of NEUROdiab (Diabetic Neuropathy Study Group). She was also the Chair of the Neuropathy Study Group of the Italian Society of Diabetology and a member of the Executive Committees of the following societies: EASD Neuropathy Study Group (NEURODIAB), the Italian Society for Neurovegetative Research and the Italian Society of Diabetology. She has been a member of the editorial board of Nutrition, Metabolism and Cardiovascular Diseases and is currently Academic Editor of the Journal of Diabetes Research and Review Editor of Frontiers in Neuropathic Pain. She has been a reviewer for 177 articles for 35 journals, including Diabetes Care, Diabetologia, Diabetes, Trends in Endocrinology and Metabolism, Molecular Metabolism and the Journal of Clinical Endocrinology and Metabolism.

She has been Chair of European Funding Review Committee and was Chair of the Consensus Panel of the Diabetic Neuropathy Study Group of the Italian Society of Diabetology and the lead author of their 2011 Recommendations on Cardiovascular tests in diabetic autonomic neuropathy. She was a member of the Toronto Consensus on Diabetic Neuropathy and the lead author of their 2011 guidelines on cardiovascular autonomic neuropathy. She was also a member of the Italian Consensus Conference on Pain in Neurorehabilitation.

She has been a Chair and invited speaker at more than 145 meetings and was the Scientific Director for two e-Learning programs of Italian Society of Diabetology on the treatment of diabetic neuropathy and neuropathic pain in 2012 and 2017-2018.

Duality of Interest: Professor Spallone has received speaker’s fees/honoraria and payment for membership of boards/advisory panels from Worwag Pharma GmbH.

Date: Winter 2022

Dr Alexis Sudlow (MB, ChB) is a bariatric research fellow and general surgery registrar at the North Bristol NHS Trust. She graduated from the University of Aberdeen in 2012.  Having been awarded a Royal College of Surgeons Fellowship grant she is currently undertaking a PhD at University College Dublin under the supervision of Professor Carel le Roux and Dr Dimitri Pournaras. Her research studies are focusing on multimodal care, combining bariatric surgery and medications to improve treatments available for patients with diabetes and obesity.

Duality of Interest: None declared

Date: Spring 2023

Dr Syed qualified at Bangalore University, India, in 1994. After a number of postgraduate training posts, he undertook specialist training in diabetes and endocrinology in the West Midlands, including a two-year lectureship at the University of Birmingham.

He completed his certificate of completion of training (CCT) in diabetes and endocrinology in 2008 and attained fellowship of the Royal College of Physicians in 2013. Dr Syed is currently a consultant physician and endocrinologist at University Hospitals Birmingham with a special interest in diabetic foot disease, lipids and cystic fibrosis-related diabetes.

He is the clinical service lead for the Diabetes Foot Service for the trust and he was selected as a Diabetes UK Clinical Champion from 2018 to 2020. His research interests include diabetic foot disease, diabetes education, and raising awareness and prevention of diabetes in ethnic minority populations. His recent publications include diabetes care during Ramadan and Hajj. He is engaged in medical education and is the lead for diabetes for fourth-year medical students and is an examiner for the fourth- and fifth-year OSCE examinations.

Duality of Interest: None declared
Date: Spring 2023

Cees Tack is Professor in Internal Medicine/Diabetology and Head of Diabetes Section at Radboud UMC, Nijmegen, The Netherlands. He received his medical degree from Radboud University in 1985, completed his residency in Internal Medicine at St Elisabeth Hospital, Amersfoort, The Netherlands and then fellowship training at Radboud University Medical Centre. In 1997, he obtained his licence to practice medicine in the USA and became a clinical associate in the National Institute of Health in Bethesda, Maryland, USA, where he researched disorders of the sympathetic nervous system in the context of diabetes, applying PET-scan procedures and norepinephrine kinetics.

In the treatment of diabetes, his patient-oriented research expertise includes the effectiveness of new glucose-lowering drugs, the role of glucose metabolism in the brain in hypoglycaemia unawareness and, currently, the role of inflammation in the relationship between obesity and insulin resistance. Amongst his recent interests are the role of digital care and multimorbidity.

Professor Tack has served as chairman of the Dutch Society for Diabetes Research and holds memberships in several other committees. In 2010, he was elected as a member of the Executive Council of the EASD. He has also served as chair of the Postgraduate Education Committee (2010-13) and previously acted as co-organiser of the EASD Annual Meeting in Amsterdam. Professor Tack has acquired several grants as a principal investigator. He has published over 300 peer-reviewed articles and contributed to several books. He is a teacher for undergraduate and graduate medical students, residents and fellows, and is actively involved in postgraduate education.

Duality of Interest: None declared
Date: Spring 2023

Roy Taylor qualified in medicine at the University of Edinburgh and is now Professor Emeritus of Medicine and Metabolism at the University of Newcastle. He was honorary Consultant Physician at Newcastle Acute Hospitals NHS Trust. He founded the Newcastle Magnetic Resonance Centre. His work encompasses application of magnetic resonance methodology to clinical medicine, metabolic research in diabetes, clinical outcome research in diabetic pregnancy, prevention of blindness by retinal screening in diabetes, and teaching in diabetes and obstetric medicine. His expertise also extends to management of pregnancy in type 1 diabetes, type 2 diabetes and gestational diabetes, and management of hyperemesis gravidarum.

His research interests include aetiological mechanisms of type 2 diabetes and clinical studies of remission of type 2 diabetes, and he has published several hundred articles. In 2011, he identified the causative mechanisms of type 2 diabetes and showed how these are returned to normal by weight loss. This has led to a series of clinical studies, including the DiRECT study, on remission of type 2 diabetes that have also confirmed and extended understanding of the aetiological mechanisms. Type 2 diabetes can now be understood as a condition of homogenous aetiology occurring in heterogenous individuals.

In the ReTUNE study, Professor Taylor’s team has established that type 2 diabetes in people who have a normal BMI is also caused by too much fat inside the liver and pancreas and that remission of diabetes can be achieved by weight loss. He has shown that type 2 diabetes is caused by the same mechanisms in obese and normal weight people.

He lectures on the new understanding of type 2 diabetes nationally and internationally, and his named lectures include the Banting Lecture of Diabetes UK in 2012, and most recently the Sir Robert W Philip Lecture of The Royal College of Physicians of Edinburgh in 2021. He was awarded the Robert Turner prize for research impact in 2023.

Duality of Interest: None declared
Date: Summer 2023

Solomon Tesfaye is a Consultant Endocrinologist at the Royal Hallamshire Hospital, Sheffield, and Honorary Professor of Diabetic Medicine at the University of Sheffield, UK. He is also Visiting Professor at Shanghai Jiao Tong University, Shanghai and Adjunct Professor at Xiangya Hospital Central Southern University, Changsha, China.

Professor Tesfaye’s research centres around the epidemiology, risk factors, pathogenesis, central nervous system involvement and treatment of diabetic neuropathy and neuropathic pain. His research has received funding from Diabetes UK, the National Institute of Health (NIH), Juvenile Diabetes Research Foundation, European Foundation for the Study of Diabetes and the National Institute for Health Research (NIHR) Health Technology Assessment.

In addition to his research projects, Professor Tesfaye has published a book, over 180 articles, reviews and book chapters in diabetic neuropathy, including a landmark study in the New England Journal of Medicine. Professor Tesfaye was Chairman of the International Expert Group on Diabetic Neuropathy, which published seven consensus recommendation papers in 2010/11, and served as Chairman of NEURODIAB – the largest global diabetic neuropathy scientific group – between 2006 and 2009. Currently, Professor Tesfaye holds positions as Associate Editor of Experimental Diabetes Research and previously of Diabetologia; he has previously served as a member of a Diabetes Review Group for the National Institute for Clinical Excellence (NICE) and recently as expert advisor to the NICE Guideline Group on management of Neuropathic Pain.

In 2014, Professor Tesfaye was presented with the honourable Camillo Golgi Prize by the European Association for the Study of Diabetes (EASD) for major scientific contributions in diabetic neuropathy. For innovative and patient-centered diabetes care, he was awarded the Arnold Bloom Lecture Award in 2017.

Duality of Interest: Professor Tesfaye has received research support/grants from Proctor & Gamble and Viatris, and speaker’s fees/honoraria from Worwag Pharma, Grunenthal, Nevro, Proctor & Gamble and Viatris. He has also received payments for membership of boards/advisory panels from Worwag Pharma, Bayer, Angelini, Proctor & Gamble and Viatris.

Date: Winter 2022

Pinnar Topsever is Professor of family medicine and chair of the department of Family Medicine at Acibadem University School of Medicine, Istanbul, Turkey. She graduated from the Istanbul University Cerrahpaşa Medical Faculty in 1998 and subsequently obtained a specialist degree in family medicine in 1999.

Her clinical and research interests include the management of diabetic individuals in primary care, epidemiology in the context of health promotion and preventative care, evidence-based medicine and research methodology. She regularly publishes the results of her research in peer-reviewed journals.

Professor Topsever is an editorial board member of several peer-reviewed scientific journals, referee in a number of scientific awards committees and has worked as a clinical referee for the Cochrane Collaboration. She has served terms on the executive committees of two EASD study groups: Hypertension in Diabetes and Primary Care. She has also served as a board member of Primary Care Diabetes Europe (PCDE) and acted as scientific secretary, local organiser of major conferences – for example, the PCDE annual conferences in 2010, 2011 and 2012 and the European General Practice Network in Antalya (2008) and Kusadasi (2013). In addition, she has served as Vice Chair (General Secretary) of PCDE in 2017 for 4 years.

She has been involved in the curriculum development and implementation of the in-service retraining of family doctors with the Turkish primary healthcare reform programme ‘Transition in Health’.

Duality of Interest: Professor Topsever has received speaker’s honorarium / fees from AstraZeneca and Novo Nordisk and board member/ advisor panel fees from Lifescan, AstraZeneca and Eli Lilly.
Date: Summer 2023

Apostolos Tsapas (MD, PhD, MSc [Oxon]) is Professor of Medicine and Diabetes at the Aristotle University School of Medicine in Thessaloniki, Greece. He serves as Head of the Second Medical Department and Director of the Diabetes Centre at Ippokratio Hospital, Thessaloniki. He is also lead investigator of the Clinical Research and Evidence-Based Medicine Unit at Aristotle University.

Professor Tsapas received his MD and PhD from Aristotle University Thessaloniki, and his MSc in Evidence-Based Healthcare from the University of Oxford. He trained in internal medicine at Aristotle University, and in diabetes at the Oxford Centre for Diabetes, Endocrinology and Metabolism. He has been on the faculty at Aristotle University since 2003 and a Senior Research Fellow in Harris Manchester College at the University of Oxford since 2008. His main research interests include knowledge synthesis (systematic reviews and meta-analyses), evidence-based practice and clinical decision making in medicine. He has authored a significant number of publications in high impact journals including the Annals of Internal Medicine, BMJ and JAMA Internal Medicine. He serves as research mentor to junior faculty, residents, and postgraduate students. In addition to his research, he sees patients with diabetes at Ippokratio Hospital, Thessaloniki.

Duality of Interest: Professor Tsapas has received research support/grants from Eli Lilly and Boehringer Ingelheim and speaker’s fees/honoraria from Novo Nordisk. He has also received payments for membership of boards/advisory panels from Boehringer Ingelheim and positions or financial relationships with Novartis.

Date: Autumn 2022

Marie Christine Vantyghem (MD, PhD) is Professor of Endocrinology-Diabetology and head of the Endocrinology-Diabetology-Metabolism and Nutrition Department at the Centre Hospitalier Régional Universitaire de Lille, France, which cares for a population of 4 million people. She belongs to the INSERM U1190 dedicated to translational research in diabetes at the European Institute for the Study of Diabetes (EGID).

Her main research areas are islet transplantation and lipodystrophy syndromes.

In the islet transplantation field, she has been involved in the very first trial in Lille (France), with Professors Francois Pattou and Julie Kerr-Conte. She was in charge of the selection and follow-up of transplanted patients with, as of 2021, a cohort of more than 60 transplanted patients. She has been involved in national islet transplantation trials, with a first randomised trial recently published as well as the ten-year results of islet-transplanted patients at Lille University Hospital.

In the lipodystrophy field, she cares for a large cohort of more than 200 patients. A biobank (plasmatheque, DNAtheque and adipose tissue bank) has been organised under the name project PHRC (Hospital Project for Clinical Research) IL7 lipodystrophies dedicated to the link between adipocytes and innate immunity. Lille University Hospital belongs to FIRENDO, a network for rare endocrine diseases, including the PRISIS reference centre, dedicated to rare diseases of insulin secretion and insulin resistance, especially lipodystrophy syndromes.

Author of more than 260 papers, Professor Vantyghem is a former member of the executive board of the French Endocrine Society, a member of the European Society of Endocrinology, the Endocrine Society, the French and European Societies of Transplantation and has been involved in two FP7 programmes. She serves as an Associate Editor for the Annals of Endocrinology.

Duality of interest: None declared

Date: Summer 2023

Prashanth Vas (MBBS, FRCP, PhD) has a decade-long experience as a Consultant in Diabetes and Diabetes Foot Medicine at King’s College Hospital – the first dedicated multidisciplinary foot clinic in the world. He is an honorary senior lecturer at King’s College London and holds an honorary visiting professorship at Staffordshire University. Prior to this, he undertook his clinical specialist training in the East of England including Addenbrookes Hospital, Cambridge, which also included a period of research at the world-renowned Ipswich Diabetes Research Unit under the guidance of Professor Gerry Rayman, leading to a PhD.

Dr Vas’s current research is focused on the lower limb complications of diabetes, including the aetiopathogenesis and treatment diabetic foot ulcers, diabetic neuropathy (especially small-fibre neuropathy) and in the validation of new techniques designed for the early detection of neuropathy. Alongside Professor Rayman, he was involved in the development of the Ipswich Touch Test, now widely recognised as a simple reliable method for assessing loss of protective foot sensation, adopted by Diabetes UK as the ‘Touch the Toes’ test. He has also been a part of two ‘Quality in Care – Diabetes’ award-winning teams and has authored more than 80 publications.

Dr Vas is currently an executive committee member of the Diabetic Foot Study Group (DFSG) and has served as an expert advisor to the UK’s National Institute of Health and Clinical Excellence (NICE) and to the International Working Group on the Diabetic Foot (IWGDF). He is the co-founder of the British Diabetic Neuropathy Symposium, which is the only academic meeting in the UK on diabetic neuropathy. In addition to maintaining an active clinical schedule at King’s College Hospital, Dr Vas continues to train and teach professionals to provide a high-quality diabetic foot and neuropathy service for patients so they can be seen as quickly as possible with the highest level of care.

Duality of Interest: None declared
Date: Summer 2023

Tina Vilsbøll(MD, DMSc) is a Clinical Professor and Head of Clinic at Steno Diabetes Center, Copenhagen, Denmark.

She has been involved in diabetes research since 1997 and in 2004 she established the Center for Diabetes Research at Gentofte Hospital, University of Copenhagen, Denmark, now part of Steno Diabetes Centre Copenhagen. Her research is focused on the pathophysiology of obesity, prediabetes, type 2 diabetes (with a specific focus on insulin, glucagon and incretin hormones), regulation of appetite and food intake, and the utilisation of incretins as therapeutics. Integration of the gut in the understanding of human glucose metabolism has become a major focus in her lab over recent years.

She has more than 300 scientific publications (H-index 64) and several published books and book chapters. Professor Vilsbøll is a frequently invited speaker at national and international meetings. Professor Vilsbøll is an experienced teacher and supervises several PhD and medical students conducting diabetes research.

In addition to her teaching and research posts, Professor Vilsbøll is a member of numerous professional societies and committees, and referees for several international journals. 

Duality of Interest: Professor Vilsbøll has received research support grants from Eli Lilly and Novo Nordisk and board member/ advisory panel fees from Boehringer Ingelheim, Eli Lilly, Novo Nordisk and Sun Pharmaceuticals. She has also received consultancy payments from Amgen, Astra Zeneca, Boehringer Ingelheim, Eli Lilly, Gilead, GlaxoSmithKline, Mundipharma, Novo Nordisk, Sanofi and Sun Pharmaceuticals.
Date: Summer 2023

Margaretha Visser obtained a master’s degree in medicine at the Rijksuniversiteit Groningen in 2011 and graduated as an endocrinologist at the University Medical Center Groningen in 2018. She then started a PhD at the department of Endocrinology, University Hospitals Leuven–KU Leuven, where she also works as a clinical assistant.

Her PhD focuses on the use of diabetes technology in type 1 diabetes and is supervised by Professors Pieter Gillard and Chantal Mathieu.

Dr Visser has published articles on this topic in journals that include The Lancet, and Diabetes Technology and Therapeutics, and has hosted webinars on continuous glucose monitoring as part of the EASD Annual Meeting.

Duality of Interest: None declared
Date: Autumn 2022

David Webb is a Consultant Endocrinologist at University Hospitals of Leicester NHS Trust and Senior Lecturer in the College of Life Sciences at the University of Leicester. His research interests centre on novel therapeutics in type 2 diabetes and obesity; vascular responses to endothelial dysfunction in chronic disease, and lifestyle-based interventions in the management and prevention of metabolic conditions. He is a senior clinician within the lifestyle and obesity theme of the Leicester NIHR Biomedical Research Centre and principal investigator for a number of studies at the Leicester Diabetes Centre. He is a fellow of the Higher Education Academy and Director the University of Leicester Diabetes Masters programme.

Duality of Interest: None declared
Date: Autumn 2022

John Wilding trained in medicine in Southampton and the Hammersmith Hospital, London, where he also undertook three years laboratory-based research into the neurobiology of obesity and diabetes. He currently works at the University Hospital Aintree, Liverpool and was appointed Professor of Medicine in 2005. He leads a clinical research group working in the field of Obesity, Diabetes and Endocrinology at the University of Liverpool, UK. Professor Wilding is a Fellow of the Royal College of Physicians.

His areas of clinical interest and expertise include type 2 diabetes and obesity where the focus of his research team centres on developing new treatments and strategies to reduce the burden of diabetes and obesity-related disease.

Professor Wilding has published over 350 original papers, chapters and review articles (ORCID ID 0000-0003-2839-8404; H index 69), which include clinical trials in diabetes and obesity, adipocyte biology and studies of metabolism. His teaching and assessment experience include being Systems Lead for years 1 and 2 for the MBChB Endocrinology at the University of Liverpool and a Founding Fellow of the World Obesity Federation Strategic Centre for Obesity Professional Education (SCOPE). He has supervised 28 higher degrees (Masters, PhDs and MDs, etc.).

Professor Wilding is Chair of the NIHR National Clinical Research Network Metabolic and Endocrine Specialty Group and immediate past President of the World Obesity Federation.  

Duality of Interest: Professor Wilding has received speaker’s fees/honoraria from Eli Lilly, Novo Nordisk, Alnylam, Boehringer Ingelheim, Mundipharma, Pfizer and Rhythm Pharm and consultancy payments from Eli Lilly, Novo Nordisk, Alnylam, Boehringer Ingelheim, Mundipharma, Pfizer and Rhythm Pharm. Please note all consultancy is contracted with and paid to Professor Wildings employer, the University of Liverpool. 
Date: Summer 2023

Bruce Wolffenbuttel graduated in medicine from Erasmus University Rotterdam, The Netherlands and is (Emeritus) Professor of Endocrinology and Metabolism at the University of Groningen, The Netherlands.

Professor Wolffenbuttel’s main research interest is ageing-related health, with a focus on the genetic and biochemical factors and gene-environment interactions in the development of endocrine disorders such as obesity and diabetes, and the pathophysiology of long-term structural and functional micro- and macrovascular complications in both human and experimental diabetes. His clinical interests include the pathology, imaging and treatment of adrenal, thyroid and pituitary disorders, as well as congenital metabolic diseases, and their effects on quality of life.

Professor Wolffenbuttel was previously scientific director and founding father of The Netherlands LifeLines population study, in which he investigated genetic and environmental factors contributing to differences in healthy ageing between individuals. He has participated in many large-scale genetic consortia.

As co-author of over 400 peer-reviewed articles he has published extensively on a diverse range of topics, including biobanking, endocrinology, diabetes and IT solutions in healthcare.

Professor Wolffenbuttel is a member of the EASD Postgraduate Education Subcommittee.

Duality of Interest: Professor Wolfenbuttel has received payments for consultancy and has other positions / financial relationships with Novo Nordisk.
Date: Winter 2022

Susan Wong trained in medicine at Kings College London, where she also gained her PhD before moving on to work at Yale University, USA. She was later awarded a Wellcome Trust Senior Clinical Fellowship in the UK and established a laboratory at Bristol University. She went on to work at Cardiff University and is now a Professor of Experimental Diabetes and Metabolism at the School of Medicine and Honorary Consultant Physician in Diabetes at the University Hospital of Wales, Cardiff.

Professor Wong has many years of research experience looking at the insulin-producing beta cells of the pancreas in type 1 diabetes. Her research primarily focuses on causes and development of type 1 diabetes and has encompassed T cell immunology, B cell immunology, regulatory T cells, innate immunity and, more recently, the role of the gut microbiome. She is a member of the UK Type 1 Diabetes Consortium and, in this role, and works on a number of projects developing immunotherapy for type 1 diabetes and in early phase 1a clinical trials.

She has published more than 150 articles and is on the editorial board of Current Molecular Medicine and Scientific Reports. She has been Chair of the Scientific Advisory Board for JDRF UK, is Deputy Chair of the Clinical Studies Group I (Pathogenesis of diabetes) of Diabetes UK, and a member of the Type 1 Diabetes UK Consortium management board. She has served on grant review panels of the NIH (Special Emphasis Diabetes), MRC, JDRF, Diabetes UK, and Hong Kong Research General Council. During her career, she has been awarded several accolades, including the Diabetes UK Dorothy Hodgkin award lecturer in 2018,  Fellow of the Learned Society of Wales in 2019 and JDRF Gerold and Kayla Grodsky award in 2021.

Duality of interest: None declared

Date: Summer 2023

Caterina Conte is Associate Professor of Internal Medicine at the San Raffaele Open University of Rome, Italy. Prior to that, she was Assistant Professor of Medicine at Vita-Salute San Raffaele University, Milan.

She qualified at Sapienza University of Rome. During her residency, she undertook a research fellowship at the Center for Human Nutrition, Washington University School of Medicine, USA, where she conducted clinical research studies involving the use of stable isotope tracers to evaluate the mechanisms responsible for the metabolic abnormalities associated with obesity. She obtained her PhD with a thesis on ‘the effect of Vitamin D supplementation on insulin resistance at the Catholic University of the Sacred Heart, Rome.

Professor Conte’s research focuses on mechanisms underlying obesity-related metabolic alterations (insulin resistance, non-alcoholic fatty liver disease, type 2 diabetes), glucose metabolism and bone health, and metabolic and bariatric surgery. She has expertise in conducting gold-standard metabolic studies for the measurement of insulin resistance (hyperinsulinaemic euglycaemic clamps).

Duality of interest: Professor Conte has received consultancy fees from Thierascience s.a.m.

Date: Autumn 2023

Billy Collins is Public Health Service Officer at the US Public Health Service Commissioned Corps. He also serves as Clinic Administrator for the National Heart, Lung and Blood Institute at the National Institute of Health.

Previous roles include Health Services Officer for the Indian Health Service on the Alabama Coushatta Tribe of Texas reservation in Polk County and Director-at-Large for the American Academy of Physician Assistants (AAPA). He also served in the AAPA House of Delegates, North Carolina Academy of Physician Assistants (NCAPA) and the Public Health Service Academy of Physician Assistants.

Dr Collins earned a Bachelor of Science degree in Respiratory Care from the University of Texas Medical Branch at Galveston, Texas, and his Master of Science degree in Physician Assistant studies at East Carolina University in Greenville, North Carolina. He received his Doctorate of Health Sciences degree from Nova Southeastern University in Fort Lauderdale, Florida. His doctoral capstone project was on the effectiveness of teaching fellowships in preparing physician assistants for academia and he received the certificate of appreciation for completing the Duke University Teaching Fellowship.

He served as a United States Public Health Service (USPHS) mentor for nearly a decade, a USPHS career development reviewer and on the admissions committee of both Duke and Campbell Universities.

Duality of interest: none declared

Date: Autumn 2023

John Buse is Verne S Caviness Distinguished Professor of Medicine and Senior Associate Dean for Clinical Research at the University of North Carolina, as well as Director of the University of North Carolina Diabetes Care Center and Director of the North Carolina Translational and Clinical Sciences Institute. He received his medical degree and PhD from Duke University, USA, before training in internal medicine and endocrinology at the University of Chicago.

His practice combines clinical care, research and education and he practises patient-centred care that focuses on developing treatment programmes in collaboration with patients. He has received international recognition for innovative clinical care and efforts at prevention of type 1 and type 2 diabetes and their complications.

He also works with teams of investigators in diabetes clinical trials, comparative effectiveness research and translation of basic science research towards clinical application. Current projects are focused on novel treatments, including development of glucose-responsive insulin, cardiovascular safety and efficacy of diabetes drugs, and developing the evidence-base for treatment guidelines of the future in diabetes care. He co-chaired the ACCORD trial and chaired the LEADER trial.

Professor Buse served as President for Medicine and Science at the American Diabetes Association in 2008 and as Chair of the National Diabetes Education Program in 2014. He has authored more than 500 publications.

Duality of interest: Professor Buse has received research support grants from Bayer, Boehringer-Ingelheim, Carmot, Corcept, Dexcom, Eli Lilly, Insulet, MannKind, Novo Nordisk, and vTv Therapeutics. These are largely clinical trial contracts, whish are paid to the University of North Carolina. In addition salary support is received from grants from the National Institutes of Health. He also receives consultancy fees from Alkahest, Altimmune, Anji, Aqua Medical Inc, AstraZeneca, Bayer, Biomea Fusion Inc, Boehringer-Ingelheim, CeQur, Corcept Therapeutics, Dasman Diabetes Center (Kuwait), Eli Lilly, embecta, Fortress Biotech, GentiBio, Glycadia, Glyscend, Janssen, MannKind, Mediflix, Medscape, Mellitus Health, Metsera, Moderna, Pendulum Therapeutics, Praetego, ReachMD, Sanofi, Stability Health, Tandem, Terns Inc, Valo and Zealand Pharma together with contracted consulting fees and travel support for contracted activities from Novo Nordisk which are paid to the University of North Carolina; which provide no direct financial benefit to him.

Professor Buse also has stock/shares in Glyscend, Mellitus Health, Pendulum Therapeutics, PhaseBio, Praetego, and Stability Health together with payment for other positions or financial relationships from Medtronic MiniMed.  

Date: Autumn 2023

Paul Valensi is a diabetologist and Professor of Nutrition at the Sorbonne Paris Nord University, former head of the Endocrinology Diabetology Nutrition Unit at the Jean Verdier Hospital, France, and co-chair of the Centre Intégré Nord Francilien Obésité Adultes et Enfants (CINFO).

He served as chairman of NEURODIAB, the Diabetic Neuropathy Study Group of the European Association for the Study of Diabetes (EASD), from 2002-05; as Chairman of the French Study Group on Heart and Diabetes (2002-05); and as Chairman of the French section of the Diabetes Education Study Group (1994-97).

He is currently president of the French Group on the Prevention of Type 2 Diabetes, a member of the executive committee of the Diabetes and Cardiovascular Disease EASD Study Group.

Professor Valensi is co-author of several French guidelines on silent myocardial ischaemia, anti-aggregants, peripheral and autonomic neuropathy in diabetes, and care of the hyperglycaemic patient during acute coronary syndrome.

He co-chaired the Toronto Consensus Panel on Diabetic Neuropathy and co-authored the European IMAGE guidelines on the prevention of type 2 diabetes. He served as a member of the taskforce for the European Society of Cardiology (ESC) guidelines on diabetes, prediabetes and cardiovascular diseases developed in collaboration with the EASD (2013 and 2019).

His main research topics are the macro- and microvascular complications of diabetes and obesity, neuropathic disorders in diabetes and obesity, and prevention of diabetes and its complications. He is the author of more than 370 articles in peer-reviewed journals and around 40 chapters in scientific books, and he is the editor or co-editor of four books.

Duality of interest: Professor Valensi has received research support/ grants from Stendo and speaker’s honorarium / fees from Novo Nordisk, AstraZeneca and Boehringer Ingelheim. He has also received board member / advisory panel payments from Novo Nordisk and Boehringer Ingelheim together with consultancy payments from Stendo, Novo Nordisk, AstraZeneca and Boehringer Ingelheim.

Date: Summer 2023

Eberhard Standl is a retired director of the Munich Diabetes Research Group e.V. at the Helmholtz Centre and Professor of Medicine, specialising in endocrinology and angiology.

He was previously director of the Department of Endocrinology, Diabetology and Metabolism at the Academic Hospital Munich Schwabing. He also worked at the world-renowned Joslin Diabetes Center in the USA and presently serves as a Vice-President of the Study Group “Diabetes and Cardiovascular Disease” as well as an associate editor of “Diabetes Research and Clinical Practice”.

Professor Standl has also served as President of the German Diabetes Association, the German Diabetes Union and the International Diabetes Federation Europe, as well as as vice president of the European Association for the Study of Diabetes (EASD).

His principal areas of research include diabetology, the action and degradation of insulin (especially clinical application of human insulin) and the pathogenesis and epidemiology of cardiovascular diabetic complications. He held leadership functions in a number of cardiovascular outcome trials.

He has published over 666 original papers, review articles, textbook chapters and monographs, and received several scientific awards, including the Bertram Award of the German Diabetes Association for research related to vascular disease in diabetes in 1981, the EASD’s Castelli-Pedroli Prize in 1999, the Harold Rifkin Award of the American Diabetes Association in 2005, the Albert Renold Medal of EASD 2006, and the Hellmut Mehnert Award 2013.

Duality of Interest: None declared

Date: Summer 2023

Roopa Mehta is an endocrinologist and researcher in the Department of Endocrinology and Metabolism at El Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (INCMNSZ) in Mexico City, Mexico. She is the director of the lipid clinic and the cardiovascular laboratory, and an associate professor in the endocrinology residency programme. She is also a principal investigator for phase 3 clinical trials and has completed a PhD in Medical Sciences. 

She completed her medical training at the United Medical and Dental Schools of Guy’s and St Thomas’ Hospital. She obtained MRCP in 2000 and trained as an endocrinologist at INCMNSZ. On completing the residency programme, she sub-specialised in diabetes and metabolism, and gained further clinical and investigative experience at the Joslin Diabetes Center in the USA.

Dr Mehta’s research interests focus on type 2 diabetes (clinical investigation), metabolic syndrome and lipid metabolism (in particular evaluation of cardiovascular risk and familial hypercholesterolemia). She has recently completed a research attachment at Imperial College, London, focusing on diabetes epidemiology.

She has presented at symposiums, including the American Diabetes Association (ADA), European Association for the Study of Diabetes (EASD) and American Association of Clinical Endocrinologists (AACE) meetings and has also presented her research in national and international meetings.

She has received the Alfonso Rivera Research Award and the Young Investigator Award from the American Association of Clinical Endocrinology. She is a member of the Mexican National Academy of Medicine.

Dr Mehta has authored and co-authored publications in international journals in addition to numerous book chapters. She is the editor in chief for Current Diabetes Reports and an associate editor for Diabetes Medicine and a reviewer for Diabetes Therapy. She is also a co-editor of a book for patients called ‘Living with Diabetes: A Practical Manual’ (currently 3^rd edition).

Duality of interest: Dr Mehta has received speaker’s honorarium / fees from Novo Nordisk, Boehringer Ingelheim, Eli Lilly and Astra Zeneca and consultancy fees from Novo Nordisk and Boehringer Ingelheim.

Date: Summer 2023

Michael Nauck is the Head of Clinical Research at the Diabetes, Endocrinology, Metabolism Section, Medical Department I, Katholisches Klinikum Bochum gGmbH, St. Josef-Hospital (Ruhr-University Bochum) in Germany. From 2000 to 2014, he was Head Physician at the Diabeteszentrum Bad Lauterberg Harz, Germany, a specialised hospital for the care and therapy of patients with diabetes and other metabolic diseases.

He has previously held clinical and research positions at leading German university departments in gastroenterology and endocrinology.

His particular research interest is in the role and impact of gastrointestinal peptide hormones in the physiological and therapeutic stimulation of insulin secretion. He has been acknowledged for major contributions to the development of new therapeutic agents for the treatment of type 2 diabetes based on anti-diabetic properties of the gut hormone GLP-1, e.g. incretin-based glucose-lowering medications (GLP-1 receptor agonists and DPP-4 inhibitors).

Additional areas of interest are spontaneous hypoglycaemia, pancreas transplantation and cardiovascular disease in people with type 2 diabetes and its modulation by different glucose-lowering therapies.

Professor Nauck has been honored with several awards for his research, including the Ferdinand-Bertram Award (1993), the Werner-Creutzfeldt Award (2007), the Paul Langerhans Medal (2012) of the Deutsche Diabetes-Gesellschaft (German Diabetes Association) and the Claude Bernard Medal of the European Association for the Study of Diabetes (2022). He is a member of multiple professional societies, including the German, European and American Diabetes Associations, the International Diabetes Federation and the American Physiological Society.

He has served as a reviewer for all major diabetes journals and has published more than 250 original articles, 150 reviews and book chapters. Michael Nauck has been identified as a “highly cited scientist” (top 1 ⁰/₀₀) by the Web of Science in 2019, 2021, and 2022.

Duality of interest: Professor Nauck has received research support / grants from Merck, Sharp & Dohme and speakers honorarium / fees from Berlin-Chemi/ Menarini, Eli Lilly & Co, Medscape, Medical Learning Institute, Merck, Sharp & Dohme, Novo Nordisk, Pfizer and Sanofi. He has also received board member / advisor panel payments from Astra Zeneca, Boehringer Ingelheim, Berlin-Chemi/ Menarini, Eli Lilly & Co, Merck, Sharp & Dohme, Novo Nordisk, Pfizer, Regor, Structure Therapeutics and Sun Pharma.

Date: Summer 2023

Francesco Giorgino is Professor of Endocrinology and Chairman of the Department of Precision and Regenerative Medicine and Ionian Area at the University of Bari Aldo Moro, Bari, Italy. He is also Chief of the Division of Endocrinology at the University Hospital Policlinico Consorziale in Bari. Professor Giorgino received his M.D. degree from the University of Bari Aldo Moro and his Ph.D. degree from the University of Naples Federico II, in Italy. After completing clinical training in endocrinology at the University of Catania, Italy, he worked at the Joslin Diabetes Center and Harvard Medical School in Boston, MA, USA, as a postdoctoral research fellow and visiting scientist (1990-1994).

Professor Giorgino has received scientific awards from various institutions, including the Juvenile Diabetes Research Foundation International (JDRF) Fellowship (New York, NY, USA), the Mary K. Iacocca Foundation Fellowship (Boston, MA, USA), the Glaxo-Wellcome Award from the European Association for the Study of Diabetes (EASD), the Aldo Pinchera and Cassano Awards from the Italian Society of Endocrinology, and the Alcmeone Award from the Italian Society of Diabetology. He has been the Italian Delegate in European Commission Cooperation in Science and Technology (COST) actions for diabetes, has been President of the Italian Society of Endocrinology (2019-2021), and is currently Senior Vice-President of the European Association for the Study of Diabetes.

He is or has been a member of the Editorial Boards for PLoS ONE, Journal of Endocrinology, Endocrinology, Journal of Endocrinological Investigation, Adipocyte, Acta Diabetologica, Cardiorenal Medicine, and Diabetes Metabolism Research and Reviews. He has published more than 300 original and review articles and has been an invited speaker at many national and international meetings. His research interests include the mechanisms of insulin resistance and beta-cell dysfunction in type 2 diabetes and the effects of diabetes drugs on pancreatic islets and the cardiovascular system. He has an H-index of 68 and 17,300 citations (Google Scholar).

Duality of interest: Professor Giorgino has received research support / grants from Eli Lilly and Roche Diabetes care and speaker’s honorarium / fees from Astra Zeneca, Boehringer Ingelheim, Eli Lilly, Lifescan, Merck, Sharp & Dohme, Medtronic, Novo Nordisk, Roche Diabetes care and Sanofi. He has also received board member / advisor panel payments from Astra Zeneca, Boehringer Ingelheim, Eli Lilly, Lifescan, Merck, Sharp & Dohme, Medimmune, Medtronic, Novo Nordisk, Roche Diabetes care, Sanofi, EASD and EFSD together with consultancy payments from Eli Lilly and Novo Nordisk.

Date: Summer 2023

Cliff Bailey is Emeritus Professor of Clinical Science in the College of Health and Life Sciences at Aston University. He was formerly Reader and Senior Lecturer in Pharmacology, and Lecturer in Physiology at the university.

His research group studies the regulation of nutrient metabolism, the pathogenesis of diabetes and obesity, and the development of new therapies, with specific interests including pathogenesis and interventional approaches against insulin resistance, and islet transplantation and therapeutic use of genetically modified insulin-releasing cells.

He is a member of multiple professional organisations, including the British Endocrine Society  and the European Association for the Study of Diabetes (EASD).

In 2021, he was named as a world expert in type 2 diabetes by Expertscape, based on his research publications over the past ten years. He contributed to the development of metformin and he and his colleagues have also been involved in the development of SGLT-2 inhibitors.   

Professor Bailey has served on the committees of Diabetes UK, the Society for Endocrinology and the EASD. He has also held several editorial positions and is currently senior editor of DVDRes.

He has been an expert witness for drug licensing authorities, regulatory agencies and other national and international review bodies, and he has published over 400 research papers and reviews.

Duality of interest: Professor Bailey has received speaker’s honorarium / fees from Merck

Date: Summer 2023

Baptist Gallwitz is Professor of Medicine at Eberhard Karls University of Tübingen in Germany and Deputy Medical Director of the Department of Diabetes and Endocrinology in the Department of Internal Medicine.

His main scientific focus is the physiology of incretin hormones and he has published over 250 original articles and reviews in international and national journals and specialist books. 

Professor Gallwitz is a member of the board of the Deutsche Diabetes Gesellschaft (DDG; German Diabetes Society) and a number of other professional associations, including the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

He has been given numerous awards and prizes for his advances in the diabetes field, including the Galileo Innovators in Diabetes and Metabolic Syndrome Award and the Werner Creutzfeldt Prize awarded by the DDG for scientific work in the field of incretin hormones.

Duality of interest: none declared

Date: Summer 2023

Paul Aveyard is Professor of Behavioural Medicine at the University of Oxford, a Fellow of Wolfson College and a practising GP. He is also theme lead for the National Institute for Health and Care Research (NIHR) Oxford Health Biomedical Research Centre (Preventing Multimorbidities), theme lead for NIHR Oxford and Thames Valley ARC (Changing Health Behaviours for Prevention) and an NIHR senior investigator.

His work focuses on helping people change their behaviour, either to prevent serious disease or as a treatment for that disease. He has examined interventions to help people stop or reduce their smoking and has worked to help people manage their weight if they have become obese.  

Professor Aveyard is former president of the UK Society of Behavioural Medicine, a former trustee of the Association for the Study of Obesity and a member of the Society for Research on Nicotine and Tobacco. He is also a senior editor of the journal, Addiction, has worked on several National Institute of Health and Care Excellence (NICE) working groups and advised the Department of Health. He is currently working with NHS England on smoking cessation and obesity.

Duality of interest: none declared

Date: Summer 2023 

Francesco Rubino is Chair of Metabolic and Bariatric Surgery in the School of Cardiovascular and Metabolic Medicine and Sciences at King’s College London, UK, and specialises in laparoscopic bariatric, metabolic and upper digestive surgery. Prior to taking up his current position, he served as the Director of the Diabetes Surgery Centre and as Chief of Gastrointestinal Metabolic Surgery at the New York Presbyterian Hospital and the Weill Cornell Medical College in New York, USA.

He received his medical degree and completed his residency in general surgery at the Catholic University/Policlinico Gemelli in Rome, Italy, and completed fellowships in laparoscopic surgery at the European Institute of Telesurgery in Strasbourg, France, the Mount Sinai Medical Center, New York, and the Cleveland Clinic, Ohio.

His research has shown that the anti-diabetes effect of certain bariatric procedures, particularly gastric bypass surgery, results from mechanisms beyond weight loss. This evidence provided a scientific rationale for surgical treatment of type 2 diabetes, including that of less obese patients. His research and theories also point to a role of the gastrointestinal tract in the pathophysiology of diabetes and obesity.

Professor Rubino was one of the co-organisers of the landmark Diabetes Surgery Summit an influential series of consensus conferences where leading international authorities reached a consensus on the best candidates for the surgical treatment of type 2 diabetes.

Duality of interest: Professor Rubino has received research support / grants from Medtronic, Ethicon Endosurg. and Novo Nordisk and speaker’s honorarium / fees from Medtronic, Ethicon Endosurg. and Novo Nordisk. He has also received board member / advisor panel payments from GT Metabolic Solution together with consultancy fees from Medtronic, Ethicon Endosurg. and GI dynamics. Professor Rubino is the president of the Metabolic Health Institute.

Date: Summer 2023

Stephen O’Rahilly is Professor of Clinical Biochemistry and Medicine and the co-director of the Wellcome-MRC Institute of Metabolic Science (IMS) at the University of Cambridge, UK. He also directs the MRC Metabolic Diseases Unit and is Head of the University Department of Clinical Biochemistry, Scientific Director of the NIHR Biomedical Research Centre and a Fellow of Pembroke College.

He qualified from University College Dublin and completed his postgraduate training in London, Oxford and Boston before setting up his laboratory in Cambridge in 1991.

He is interested in the aetiology and pathophysiology of human metabolic and endocrine disease, and how such information might be used to improve the diagnosis, therapy and prevention of these diseases. One major area of continuing interest is to better understand why some people are susceptible to obesity and others seem resistant.

He was elected to the Royal Society in 2003, a Foreign Associate of the National Academy of Sciences USA in 2011 and was appointed a Knight Bachelor in 2013. His findings have been recognised internationally with multiple awards, including the Association of Physicians (AoP) highest award for an Outstanding Contribution to Translational Medicine in 2023.

Duality of interest: Professor Sir Stephen O’Rahilly has received research support / grants from MRC and Wellcome and speaker’s honorarium / fees from Royal Society Award and University of Chicago lectures. He has also received board member / panel payments from Astra Zeneca and Pfizer together with consultancy fees from Astra Zeneca, Pfizer, Third Rock Ventures and Novo Nordisk.

Date: Summer 2023

Jason Gill is Professor of Cardiometabolic Health in the Institute of Cardiovascular and Medical Sciences at the University of Glasgow. He leads an active multi-disciplinary research group investigating the prevention and management of vascular and metabolic diseases and has published more than 200 peer-reviewed papers on these topics.

This work includes studies into the epidemiology of lifestyle-related factors (principally physical activity, diet and sleep) and cardiometabolic disease risk, particularly why certain population groups appear to have increased susceptibility to the adverse effects of an ‘unhealthy’ lifestyle; lifestyle interventions for the prevention and management of cardiometabolic disease; and investigations into the mechanisms by which diet and exercise regulate insulin sensitivity and lipoprotein metabolism. 

In recent years, he has become increasingly focused on collaborative projects involving biological and medical scientists working together with social scientists and external stakeholders to develop realistic and sustainable lifestyle interventions for the primary and secondary prevention of chronic diseases. 

Professor Gill has contributed to the UK Physical Activity guidelines, NICE guidelines for prevention of type 2 diabetes, and SIGN guidelines for obesity and cardiovascular disease. He is chair of the Diabetes UK Research Strategy Group for Prevention and Management of Type 2 diabetes, and an editor at several journals including the British Journal of Sports Medicine and the Journal of Sports Sciences. 

In addition, he is Director of the MSc in Sport and Exercise Science & Medicine at the University of Glasgow and plays an active role in communicating science related to physical activity, diet and obesity to the widest possible audience including a number of appearances on TV documentaries.

Duality of interest: None declared

Date: Summer 2023

Dominik Pesta is currently a group leader at the German Aerospace Center, Institute of Aerospace Medicine and a tenure-track professor of ‘Translational Metabolism’ at the Center for Endocrinology, Diabetes and Preventive Medicine (CEDP) at the University Hospital Cologne. He was previously Senior Postdoctoral Fellow at the German Diabetes Center in Düsseldorf and was awarded an Erwin Schrödinger fellowship granted by the Austrian Science Fund for a research stay at Yale University, New Haven, CT.

Professor Pesta’s research focuses on how exercise affects energy metabolism and mitochondrial function and its significance as a countermeasure in spaceflight-induced deconditioning as well as for prevention and treatment of metabolic diseases such as diabetes.

In his capacity as chairman of the EASD Exercise and Physical Activity Study group (ExPAS), he promotes communication, scientific collaborations and clinical education in the areas that link exercise sciences to metabolism and diabetes.

Duality of interest: None declared

Date: Summer 2023

Richard Bracken is Professor of Exercise Physiology at Swansea University where he contributes to teaching, research and innovation activities in the Faculty of Medicine, Health and Life Sciences and Faculty of Science and Engineering. He is co-Director of Interdisciplinary Research Institute in Health and Technology at Swansea University.

He has a specialist interest in the interactions of medication, nutrition and technology around exercise in diabetes and obesity.   

Professor Bracken is Vice-Chair for the Exercise and Physical Activity study group (ExPAS) of the European Association for the Study of Diabetes (EASD) and is passionate about promoting the positive role of physical exercise in the management of metabolic conditions.

He has active global research links, with colleagues in Canada, USA and Europe (Austria, Germany, Denmark, Ireland, Sweden, Switzerland, Spain and Italy) and has published numerous papers on his specialist research area.

Duality of interest: None declared

Date: Summer 2023

Tsvetalina Tankova is Professor of Endocrinology, Chair in Endocrinology and Vice Rector at the Medical University of Sofia, Bulgaria. She is also Head of the Department of Diabetology at the University Hospital of Endocrinology in Sofia.

She graduated from the Medical University of Sofia, Bulgaria, where she obtained her PhD and DMedSc degree, as well as a specialist degree in internal medicine and endocrinology. She has a Master’s degree in public health and healthcare management. She was trained at the WHO Collaborating Center, University Hospital, Geneva; Switzerland; King’s College Hospital, London, UK, and the Steno Diabetes Center, Copenhagen, Denmark.

Professor Tankova is author and co-author of over 260 articles in national and international peer-reviewed journals like Diabetes Research and Clinical Practice, Diabetes Care, Diabetologia, Diabetes Obesity and Metabolism, Nutrients, etc. She is co-author in the recent ADA/EASD Consensus report on the management of hyperglycemia in type 2 diabetes, 2022. She has over 460 presentations at national and international congresses and symposia.

Professor Tankova has been a principal investigator in over 40 university-funded research projects and international clinical trials in diabetes.

She teaches medical students in endocrinology and postgraduate students in diabetes. She received the Best Teacher award of the Faculty of Medicine in 2017. She is involved in multiple postgraduate courses in practical diabetology and diabetes research. She is an invited speaker at EASD postgraduate training courses in many countries. She has supervised many PhD theses and postgraduate students.

Professor Tankova chairs the Examination committee for the state exam for specialist degree in endocrinology.

She is a member of a range of national and international committees. She is Chair of the Expert Council on Endocrinology at the Bulgarian Ministry of Health, and is a member of the Guidelines Oversight Committee at the EASD.

She is a member of many societies and associations and has been Secretary of the Bulgarian Society of Endocrinology since 2003.

She serves as Editorial Board member and reviewer at a number of national and international journals in the field of diabetes and metabolism.

Professor Tankova is the recipient of many awards, including the prestigious Pythagoras Prize of the Ministry of Education and Science, and the National Medical Award 2020.

Her clinical areas of interest include diabetes, prediabetes, obesity, metabolic syndrome. Her research activity is focused on risk factors and prevention of type 2 diabetes, complications in prediabetes, glucose variability in prediabetes, cardiovascular autonomic dysfunction in prediabetes and diabetes, diabetic polyneuropathy, vitamin D in diabetic neuropathy and diabetic foot, metabolic disturbances in type 1 diabetes, monogenic diabetes, novel glucose-lowering agents.

Duality of Interest: Professor Tankova has received speaker’s fees/honoraria from Novo Nordisk, Boehringer Ingelheim, Astra Zeneca, Eli Lilly and has also received payments for membership of boards/advisory panels from Boehringer Ingelheim, Novo Nordisk, Astra Zeneca, Eli Lilly.

Date: Autumn 2023 

Geltrude Mingrone is Professor of Internal Medicine at the Catholic University in Rome, Italy, and Professor of Diabetes and Nutrition at King’s College London, UK. She completed her medical training and residency in endocrinology and gastroenterology at the Catholic University/Policlinico Gemelli in Rome, and obtained a PhD in clinical pharmacology at the University of Ghent in Belgium.

Her research focuses on the role of the small intestine in insulin resistance, type 2 diabetes and non-alcoholic fatty liver disease (NAFLD). She is an expert in energy expenditure and metabolism regulation using indirect calorimetry and, in particular, the calorimetric chamber where a subject stays for 24 hours in near free-living conditions. She studies body composition with MRI and DEXA. She also investigates insulin sensitivity and fat metabolism with stable isotope infusion and euglycaemic hyperinsulinaemic clamp. She is the author of over 350 articles in peer-reviewed journals and book chapters.

Professor Mingrone has received numerous awards and has given hundreds of presentations throughout the world. She contributed (and is still contributing to) the ADA/EASD guidelines for the treatment of type 2 diabetes.

Duality of Interest: Professor Mingrone has received speaker’s fees/honoraria from Recor Ltd together with payments for membership of boards/advisory panels from Novo Nordisk, Boehringer Ingelheim, Fractyl Inc, Metadeq Inc, GHP Scientific Ltd and Jemyll Ltd. She has also received payments for other educational activities from Novo Nordisk.

Date: Autumn 2023 

Vanita Aroda is the Director of Diabetes Clinical Research at the Brigham and Women’s Hospital in Boston, MA, and is an Associate Professor of Medicine at Harvard Medical School. She completed her training in Internal Medicine and in Endocrinology, Diabetes and Metabolism at the University of California San Diego, CA, USA.

Professor Aroda has an interest and published record in diabetes prevention and novel therapeutics in diabetes and weight management. She also has a strong interest in understanding therapeutic interventions in large multicentre clinical trials and their applicability and integration into care. She has years of experience in clinical trial conduct and leadership, has served as an investigator on multiple National Institutes of Health-funded studies, and as the national or international signatory principal investigator for multiple therapeutic clinical trials.

Professor Aroda served on the Professional Practice Committee of the American Diabetes Association (ADA) Standards of Care in Diabetes 2021, 2022 and 2023, and on the international 2022 ADA/EASD consensus group for the management of hyperglycaemia in type 2 diabetes.

Duality of interest:  

Professor Vanita Aroda has received research support/grants from Applied Therapeutics, Eli Lilly, Fracytl, Novo Nordisk and Sanofi together with consultancy fees from Applied Therapeutics, Fracytl, Pfizer, Novo Nordisk and Sanofi.

Date: Autumn 2023

Patrick MacDonald is a Professor in the Department of Pharmacology at the University of Alberta in Edmonton, Canada, and Director of the Alberta Diabetes Institute IsletCore human research islet program. He obtained his PhD in Physiology from the University of Toronto in 2003, then carried out his post-doctoral fellowship training in Lund, Sweden, and Oxford, UK, before establishing his independent research laboratory at the Alberta Diabetes Institute in Edmonton in 2006.

His group’s main interests lie in understanding the mechanisms that control hormone release from the endocrine pancreatic islets of Langerhans and how this is disrupted in diabetes. They study the control of both insulin and glucagon secretion, with a particular interest in elucidating the signalling mechanisms that control key ion channels and exocytotic processes responsible for secretion. They have a major interest in asking these questions, not only in standard experimental models such as cell lines and rodent islets, but also in pancreatic islets isolated from human donors. They run a human research islet program, aimed at understanding the mechanisms that control human islet function in health and disease.

Professor MacDonald has received new investigator awards from the American Physiological Society, the Canadian Society of Pharmacology and Therapeutics and Diabetes Canada. He recently held a Killam Annual Professorship at the University of Alberta and was elected as a member of the College of the Royal Society of Canada.

He has served on numerous panels and boards, including Diabetes Canada and Canadian Institutes of Health Research granting and personnel awards committees, the editorial boards of Endocrinology and Diabetes and as associate editor of Islets and AJP – Endocrinology and Metabolism, and Diabetologia.

Duality of Interest: None declared
Date: Spring 2023

Emma Wilmot is an associate professor at the University of Nottingham with an honorary role as Consultant Diabetologist at Derby Teaching Hospitals NHS Foundation Trust. She qualified from the University of Glasgow and completed a PhD on type 2 diabetes in younger adults and sedentary behaviour at the University of Leicester, under the supervision of Professors Melanie Davies and Kamlesh Khunti.

Dr Wilmot specialises in insulin pump therapy, antenatal diabetes and young adult diabetes in addition to integrated community diabetes care. She has an active interest in diabetes research and is a principal investigator on diabetes research trials. She was awarded the University of Leicester College of Medicine, Biological Sciences and Psychology prize for excellent PhD performance.

She is the founder of the ABCD Diabetes Technology Network (www.dtn-uk.care), which aims to improve access to diabetes technologies for people with diabetes. As Chair, she previously led the delivery of educational events for multidisciplinary diabetes teams and the development of a suite of national diabetes technology best-practice guides, in addition to online modules for people living with diabetes.

She is an executive board member for the UK structured education programme for type 1 diabetes ‘Dose Adjustment for Normal Eating’ (DAFNE), an elected member of the ABCD committee and an invited speaker at a range of national and international diabetes meetings. She is also a member of the National Diabetes Audit Insulin Pump Expert Reference Group and has been involved in the #languagematters movement.

Duality of Interest: Dr Wilmot has received speaker’s fees/honoraria from Abbott, Dexcom, Eli Lilly & Company, Insulet, Sanofi and Novo Nordisk. She has also received payments for membership of boards/advisory panels from Abbott, Dexcom, Eli Lilly & Company, Insulet and Sanofi together with payments for other education activities from Novo Nordisk.

Date: Winter 2022

Chris Salisbury is Professor of Primary Health Care at Bristol Medical School, UK, and a National Institute for Health and Care Research (NIHR) Senior Investigator. He studied medicine at the University of Bristol and became a full-time GP in Reading, UK. During his time in this position, he studied for a Masters degree in General Practice, and was a GP trainer and Postgraduate Tutor at the Royal Berkshire Hospital in Reading.

Professor Salisbury’s research interests include the ways healthcare should address the challenge of the growing number of people with multimorbidity. He is passionate about reducing health inequalities and improving care for the groups of patients in need, including the ageing population. In particular, he has an interest in improved opportunities for care of patients with complex, multiple problems, and strives to offer patients individual ‘whole-person’ care.

He has published five books and over 230 research papers on the topic of improved delivery of primary care. He conducted the first study of the epidemiology of multimorbidity in the UK, and published systematic reviews on the prevalence, outcomes and measurement of multimorbidity.

Professor Salisbury has developed and evaluated interventions to improve chronic disease management, including the largest ever trial of an intervention for patients with multimorbidity, known as ‘the 3D trial’. He has conducted several high-profile reviews of new models of care, such as changes in out-of-hours arrangements, NHS walk-in centres, GPs with special interests, telehealth for chronic disease management, and the potential of new forms of consultation such as e-consultations.

He has been a board member for the National Institute for Health and Care Research (NIHR) Health Services & Delivery Research programme and the NIHR School for Primary Care Research, chair of the Royal College of General Practitioners (RCGP) Scientific Foundation Board and RCGP Research Paper of the Year Panel, as well as a member of several other national and international boards and advisory bodies. He has been a member of the NIHR Advanced Fellowships Panel and the Taskforce on Multiple Conditions established by the Richmond Group of Charities. In December 2018, he gave the prestigious James Mackenzie lecture at the RCGP Annual General Meeting, entitled ‘Designing health care for the people who need it’.

He regularly lectures on multimorbidity. He supervises Academic Foundation Doctors, Academic Clinical Fellows and PhD students interested in an academic career. He also advises and mentors a number of early-career academics from clinical and science backgrounds.

Duality of Interest: None declared
Date: Spring 2023

Lisa Marie Nicholas leads the Epigenetics in Diabetes research group at the University of Adelaide. Prior to this, she completed post-doctoral training mentored by Professor Hindrik Mulder at Lund University Diabetes Centre to understand the role of mitochondria in maintaining beta-cell function. Following her time in Sweden, Dr Nicholas moved to the University of Cambridge, funded by an Australian Health and Medical Research Council C J Martin Fellowship, to study the mechanisms underpinning the relationship between exposure to maternal obesity and beta-cell dysfunction in the offspring, with Professor Susan Ozanne.

Building on her expertise in this area, Dr Nicholas’ research group is focused on defining the epigenetic determinants of pancreatic beta-cell dysfunction in offspring exposed to maternal hyperglycaemia and how this is driving an intergenerational cycle of diabetes. This is being achieved using both animal models of developmental programming and by studying the blood epigenetic landscape of Australian Aboriginal children born to mothers with diabetes in pregnancy.

Duality of Interest: None declared

Date: Winter 2022